The Incorporation of Decellularized Cardiac ECM into Fibrin Microthreads by Marengo, Kaitlyn A
Worcester Polytechnic Institute
Digital WPI
Masters Theses (All Theses, All Years) Electronic Theses and Dissertations
2017-05-26
The Incorporation of Decellularized Cardiac ECM
into Fibrin Microthreads
Kaitlyn A. Marengo
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/etd-theses
This thesis is brought to you for free and open access by Digital WPI. It has been accepted for inclusion in Masters Theses (All Theses, All Years) by an
authorized administrator of Digital WPI. For more information, please contact wpi-etd@wpi.edu.
Repository Citation
Marengo, Kaitlyn A., "The Incorporation of Decellularized Cardiac ECM into Fibrin Microthreads" (2017). Masters Theses (All Theses, All
Years). 843.
https://digitalcommons.wpi.edu/etd-theses/843
  The Incorporation of Decellularized Cardiac ECM into 
Fibrin Microthreads  
 
Kaitlyn Amié-Elizabeth Marengo 
A thesis to be submitted to the faculty of Worcester Polytechnic Institute in partial fulfillment of the 
requirements for the Degree of Master of Science 
 
Submitted by: 
Kaitlyn A Marengo 
Department of Biomedical Engineering 
 
____________________________ 
 
Approved by: 
 
Glenn R Gaudette, PhD 
Associate Professor 
Department of Biomedical 
Engineering  
 
 
_______________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Raymond L Page, PhD 
Professor of Practice 
Department of Biomedical 
Engineering 
 
 
_______________________ 
 
 
 
 
 
May 31, 2017 
 
 
 
 
 
 
 
 
George D Pins, PhD 
Associate Professor 
Department of Biomedical 
Engineering 
 
 
______________________
1 
 
Abstract 
Stem cell therapies have shown promising capabilities in regaining the functionality of scar tissue 
following a myocardial infarction. Biological sutures composed of fibrin have been shown to more 
effectively deliver human mesenchymal stem cells (hMSCs) to the heart when compared to traditional cell 
delivery mechanisms. While the biological sutures do show promise, improvements can be made. To 
enhance the fibrin sutures, we propose to incorporate native cardiac extracellular matrix (ECM) into the 
fibrin microthreads to produce a more in vivo-like environment. This project investigated the effects that 
ECM incorporation has on fibrin microthread structure, mechanics, stem cell seeding, and pro-angiogenic 
potential. Single microthreads composed of fibrin or fibrin and ECM were subjected to uniaxial tensile 
testing. It was found that the microthreads consisting of both fibrin and ECM had significantly high elastic 
moduli than fibrin only microthreads. Cell seeding potential was evaluated by performing a 24-hour hMSC 
seeding experiment using sutures of the varying microthread types. A CyQuant cell proliferation assay was 
used to determine the number of cells seeded onto each suture type. The results determined that there 
was no statistical difference between the numbers of cells seeded on the types of sutures. To examine 
the pro-angiogenic potential the microthreads had, a 24-hour endothelial progenitor outgrowth cell 
(EPOC) outgrowth assay was used. Fibrin and 15% ECM-fibrin microthreads were placed within the scratch 
of an EPOC culture and evaluated every 6 hours for 24 hours. We found that the 15% ECM microthreads 
had significantly increased the EPOC outgrowth, approximately 16% more distance travelled than fibrin 
microthreads and 18% more than no microthreads. Our combined results suggest that ECM does not 
affect hMSC attachment to biological sutures but does increase the pro-angiogenic potential of the 
microthreads due to their increase in guiding EPOC outgrowth. 
  
2 
 
Acknowledgements 
 
First, I would like to thank my advisor Glenn Gaudette for his constant feedback, support, insight 
and guidance throughout the course of this project as well as my time here at WPI as both an 
undergraduate student and a graduate student. I would also like to thank my committee members 
Raymond Page and George Pins for their help in guiding me through this project. I would like to express 
my sincerest gratitude to all the members of the Gaudette Lab. Katrina Hansen, Joshua Gershlak, and 
Emily Robbins, you have all been so supportive and I am so grateful for all the times you helped or 
assisted me with an experiment or taught me a new lab technique. I am also so grateful for you helping 
me through writing my thesis as well as editing and helping me practice for my final presentation. Many 
thanks to the Biomedical Engineering Department at WPI for the use of their resources as well as the 
guidance through my graduate studies. Finally, I would like to extend a special thank you to my parents, 
brothers, family, and boyfriend Adam for their love and support throughout the past two years. I don’t 
think I could have made it this far without any of them.  
  
3 
 
Table of Contents 
Abstract ......................................................................................................................................................... 1 
Acknowledgements ....................................................................................................................................... 2 
Table of Figures ............................................................................................................................................. 6 
List of Tables ................................................................................................................................................. 9 
Chapter 1: Introduction .............................................................................................................................. 10 
Chapter 2. Background ............................................................................................................................... 10 
2.1 Myocardial Function and Myocardial Infarction ............................................................................... 10 
2.2 Clinical Treatments ........................................................................................................................... 12 
2.3 Cellular Therapies for Tissue Regeneration ...................................................................................... 14 
2.3.1 Mesenchymal Stem Cells for Cardiac Repair ............................................................................. 14 
2.4 Fibrin ................................................................................................................................................. 16 
2.4.1 Fibrin Scaffolds for Tissue Engineering ...................................................................................... 16 
2.4.2 Fibrin Microthreads.................................................................................................................... 17 
2.5 Extracellular Matrix ........................................................................................................................... 18 
2.5.1 Proteins of the Extracellular Matrix ........................................................................................... 19 
2.5.2 Integrin Binding .......................................................................................................................... 20 
2.5.3 Growth Factors........................................................................................................................... 21 
2.5.3 Extracellular Matrix Based Scaffolds .......................................................................................... 22 
2.5.4 Extracellular Matrix Based Treatments for Cardiac Repair ........................................................ 23 
Chapter 3: Hypothesis and Specific Aims .................................................................................................... 26 
Chapter 4: Aim #1: Produce ECM Microthreads, Confirm ECM Incorporation and Test for Mechanical 
Properties .................................................................................................................................................... 28 
4.1 Introduction ...................................................................................................................................... 28 
4.2 Methods ............................................................................................................................................ 28 
4.2.1 Rat Heart Decellularization Process ........................................................................................... 28 
4.2.2 Decellularized ECM Lyophilization ............................................................................................. 30 
4.2.3 Lyophilized ECM Solubilization .................................................................................................. 32 
4.2.4 ECM-Fibrin Microthread Co-Extrusion ....................................................................................... 33 
4.2.5 Immunohistochemical Staining for Cardiac Extracellular Matrix Proteins ................................ 36 
4.2.6 Structural Analysis of ECM-Fibrin Microthreads ........................................................................ 37 
4.2.7 Tensile Testing of ECM-Fibrin Microthread Mechanical Properties .......................................... 38 
4.2.8 Statistical Analysis ...................................................................................................................... 41 
4 
 
4.3 Aim 1 Results ..................................................................................................................................... 41 
4.3.1 Immunohistochemical Staining Results ..................................................................................... 41 
4.3.2 Microthread Diameter Results ................................................................................................... 44 
4.3.3 Microthread Mechanical Testing Results ................................................................................... 46 
4.4 Aim 1 Discussion ............................................................................................................................... 51 
4.4.1 Microthread Diameters .............................................................................................................. 51 
4.4.2 Microthread Mechanics ............................................................................................................. 52 
Chapter 5 Aim #2: Human Mesenchymal Stem Cell Seeding on Fibrin-ECM Sutures ................................ 54 
5.1 Introduction ...................................................................................................................................... 54 
5.2 Methods ............................................................................................................................................ 54 
5.2.1 ECM-Fibrin Microthread Bundle Making ................................................................................... 54 
5.2.2 ECM-Fibrin Suture Production ................................................................................................... 55 
5.2.3 Cell Culture ................................................................................................................................. 57 
5.2.4 Suture Seeding ........................................................................................................................... 57 
5.2.5 Cell Seeding Quantitative Analysis: CyQuant Cell Proliferation Assay ....................................... 58 
5.2.6 Cell Seeding Qualitative Analysis: Hoescht and Phalloidin Fluorescent Staining ...................... 62 
5.3.7 Statistical Analysis ...................................................................................................................... 63 
5.3 Aim 2 Results ..................................................................................................................................... 63 
5.3.1 CyQuant Cell Proliferation Assay ............................................................................................... 63 
5.3.2 Hoescht and Phalloidin Immunohistochemistry ........................................................................ 64 
5.4 Aim 2 Discussion ............................................................................................................................... 66 
Chapter 6: Aim #3: Evaluate Endothelial Progenitor Outgrowth Cell Outgrowth ...................................... 68 
6.1 Introduction ...................................................................................................................................... 68 
6.2 Methods ............................................................................................................................................ 68 
6.2.1 Cell Culture ................................................................................................................................. 68 
6.2.2 Microthread Sample Preparation for Outgrowth ...................................................................... 69 
6.2.3 Endothelial Progenitor Outgrowth Cell Outgrowth ................................................................... 71 
6.2.4 DAPI Staining .............................................................................................................................. 72 
6.2.5 Cell Outgrowth Evaluation ......................................................................................................... 73 
6.2.6 Microthread Media Control ....................................................................................................... 75 
6.2.7 Statistical Analysis ...................................................................................................................... 76 
6.3 Aim 3 Results ..................................................................................................................................... 76 
6.3.1 Endothelial Progenitor Outgrowth Cell Migration ..................................................................... 76 
5 
 
6.3.2 Evaluation of Endothelial Progenitor Outgrowth Cell Outgrowth ............................................. 78 
6.3.3 Endothelial Progenitor Outgrowth Cell DAPI Stain .................................................................... 80 
6.4 Aim 3 Discussion ............................................................................................................................... 83 
Chapter 7: Future Work and Recommendations ........................................................................................ 85 
Chapter 8: Conclusion ................................................................................................................................. 88 
References .................................................................................................................................................. 89 
Appendix A: Cardiac ECM Preparation ....................................................................................................... 95 
A.1. Decellularization of Cardiac Tissue .................................................................................................. 95 
A.2. Lyophilization of Decellularized Cardiac ECM.................................................................................. 95 
A.3. Solubilization of Cardiac ECM .......................................................................................................... 96 
Appendix B: ECM-Fibrin Microthread Production ...................................................................................... 97 
Appendix C: ECM Protein Staining Protocols ............................................................................................ 100 
Appendix D: Suture Production ................................................................................................................ 101 
Appendix E: hMSC Seeding Protocol ......................................................................................................... 103 
Appendix F: CyQuant Cell Proliferation Assay Protocol ............................................................................ 105 
Appendix G: Hoescht and Phalloidin Staining Protocol ............................................................................ 108 
Appendix H: EPOC Outgrowth Assay Protocol .......................................................................................... 109 
H.1. Microthread Construct Preparation .............................................................................................. 109 
H.2. Plate Preparation and Cell Culture ................................................................................................ 109 
H.3. EPOC Outgrowth Assay .................................................................................................................. 110 
Appendix I: DAPI Staining Protocol ........................................................................................................... 111 
Appendix J: EPOC Outgrowth Calculations ............................................................................................... 112 
 
  
6 
 
Table of Figures 
Figure 1 Diagram of the Extracellular Matrix [57] ...................................................................................... 19 
Figure 2 Left: Full hearts obtained from adult Sprague Dawley rats. Middle: Heart tissue minced into 
small pieces. Right: Decellularized cardiac tissue. .............................................................................. 30 
Figure 3 Decellularized ECM frozen in approximately 10mL of DI water prepared for lyophilization. ...... 31 
Figure 4 Decellularized ECM has been lyophilized at -104.3°C and 14mTorr for approximately 48 hours 32 
Figure 5 Solubilization process of decellularized ECM. Left: 100mg of the lyophilized ECM is measured 
and placed into a glass scintillation vial. Middle: A solution of 10mg of pepsin and 10ml of 0.1M HCl 
is added to the ECM. Right: The ECM is fully solubilized following 5 days of constant stirring. ........ 33 
Figure 6 Microthread Mechanical Tensile Testing Constructs. ................................................................... 39 
Figure 7 Modified Steel Alligator Clips for Microthread Tensile Testing. ................................................... 40 
Figure 8 Immunofluorescence of ECM-fibrin microthreads that had been stained for Collagen I. A. 
Inverted fluorescent microscope images of the microthreads. B. Confocal microscope images of the 
microthreads. Scale bar=100um ......................................................................................................... 42 
Figure 9 Immunofluorescence of ECM-fibrin microthreads that have been stained for Laminin 111. A. 
Inverted fluorescent microscope images of the microthreads. B. Confocal microscope images of the 
microthreads. Scale bar=100um ......................................................................................................... 43 
Figure 10 Immunofluorescence of ECM-fibrin microthreads that have been stained for Fibronectin. A. 
Inverted fluorescent microscope images of the microthreads. B. Confocal microscope images of the 
microthreads. Scale bar=100um ......................................................................................................... 43 
Figure 11 Comparison of average Right: dry diameters and Left: wet diameters of the fibrin and ECM-
fibrin microthreads. An asterisk (*) is used to indicate a statistical significance. * p<0.001, ** 
p<0.0001, n=8 microthreads ............................................................................................................... 45 
Figure 12 Comparison of the average swelling percentage for each ECM-fibrin microthread type. ......... 46 
Figure 13 Ultimate tensile strength results for the varying ECM-fibrin microthread types. (n=32, n=33, 
n=33, n=25) ......................................................................................................................................... 47 
Figure 14 Strain at failure (mm/mm) results for the varying ECM-fibrin microthread types. (n=29, n=30, 
n=32, n=24) ......................................................................................................................................... 48 
Figure 15 Elastic modulus results of the varying types of ECM-fibrin microthread types. (n=29, n=33, 
n=32, n=21). An asterisk (*) is used to indicate a statistical difference between the elastic moduli for 
the 10% ECM microthreads and the fibrin microthreads. *p<0.05 .................................................... 49 
Figure 16 Mean elastic moduli (MPa) for the varying types of ECM-fibrin microthreads. (n=29, n=33, 
n=32, n=21). An asterisk (*) is used to indicate a statistical difference between the elastic modulus 
for the 10% ECM microthreads and the fibrin microthread modulus. *p<0.05 ................................. 50 
7 
 
Figure 17 Microthread bundling process. Left: 12 individual microthreads are bound together with lab 
tape. Middle: Microthread cluster is hung on a lab stand and hydrated with DI water and then 
twisted together. Right: The bundle is stretched taught to dry. ........................................................ 55 
Figure 18 A. A 5cm section of a bundle is cut. B. The bundle is threaded through the eye of a needle. The 
bundle will then be hydrated to 20 minutes in DPBS. C. The hydrated bundle is twisted together and 
stretched between two hemostats. D. A 2 cm fibrin suture. ............................................................. 56 
Figure 19 Suture housed inside a bioreactor. Gas permeable silicone tubing s used to allow ethylene 
oxide sterilization to occur as well as gas exchange for cell survival during seeding. A 27G needle 
will be used to deliver DPBS and the cell suspension. The slide clamps are used to create a seal and 
hold the cells within the bioreactor. ................................................................................................... 57 
Figure 20 Schematic of a 96-well plate used for CyQuant cell proliferation assay. In Columns 1-4 and 
Rows A-H, a standard curve is created to correlate the amount of DNA detected on the sutures to a 
set number of cells. ............................................................................................................................. 60 
Figure 21 Complete 96-well plate used for CyQuant. This first plate contains the standard curve as well 
as seeded and control suture samples for each suture type. ............................................................. 61 
Figure 22 The orientation of samples for the second 96-well plate used for CyQuant. ............................. 61 
Figure 23 Cell Seeding of the varying types of fibrin-ECM microthreads quantified using a CyQuant DNA 
Assay, n=15 ......................................................................................................................................... 64 
Figure 24 Fluorescent inverted microscope images of seeded sutures after being stained for hoescht (cell 
nuclei) and phalloidin (f-actin) taken at 10X magnification. Left: Images of the sutures taken using 
the Hoescht objective Middle: Images of the sutures taken using the Fluor 488 (Phalloidin) 
objective Right: An overlay of the two channels. Scale bar=100um .................................................. 65 
Figure 25 Confocal fluorescent microscope images of seeded sutures after being stained for hoescht (cell 
nuclei) and phalloidin (f-actin). ........................................................................................................... 66 
Figure 26 Schematic of the 6-well plate used for the outgrowth assay. Each plate was marked with 2 
parallel dotted lines prior to cell culture. ........................................................................................... 69 
Figure 27 Microthread construct consisting a stainless-steel washer and a section of a polypropylene 50 
mL conical tube These two components are brought together using silicone adhesive. Finally, the 
microthread is placed in the middle of the construct. ....................................................................... 71 
Figure 28 Schematic of a 6-well plate that has been prepared for the EPOC Outgrowth assay. The scratch 
has been made and the microthread constructs have been placed within the scratch. ................... 72 
Figure 29 Ten horizontal lines are drawn in parallel across the scratch and then measured using the 
measuring function in ImageJ. ............................................................................................................ 74 
Figure 30 Ten measurements are made for a single image in ImageJ to calculate the average distance 
between the scratch for this image. ................................................................................................... 74 
Figure 31 EPOC outgrowth progression over 24 hours under the conditions of a control (no 
microthreads), a fibrin microthread and a 15% ECM microthread. ................................................... 77 
8 
 
Figure 32 Outgrowth of EPOCs over time. .................................................................................................. 78 
Figure 33 Mean percent change in distance between the edges of the scratch for each outgrowth 
condition. An asterisk (*) is used to indicate a statistical difference between outgrowth conditions. 
*p<0.0001. n=6 ................................................................................................................................... 79 
Figure 34 A comparison of the initial and final distances for each outgrowth condition. An asterisk (*) is 
used to indicate significance between the final distances between the scratch. *p<0.0001 ............ 80 
Figure 35 15% ECM microthreads stained for DAPI (cell nuclei) following Left: a 24-hour EPOC outgrowth 
assay Right: a 24-hour EPOC media control incubation ..................................................................... 81 
Figure 36 Fibrin microthread stained for DAPI (cell nuclei) following Left: a 24-hour EPOC outgrowth 
assay Right: a 24-hour EPOC media control incubation ..................................................................... 81 
Figure 37 Mean number of EPOCs counted on microthreads following a 24-hour outgrowth assay. ....... 82 
  
9 
 
List of Tables 
Table 1 Integrin-Ligand Binding Specificity [71] .......................................................................................... 21 
Table 2 Volumes of ECM solution and fibrinogen and thrombin to make ECM-Fibrin microthreads. ....... 35 
Table 3 The final concentrations of fibrinogen, thrombin and ECM calculated based on the final ECM 
solution volume for each thread type. ............................................................................................... 36 
Table 4 Concentrations for IHC protein staining for major cardiac proteins. ............................................. 37 
Table 5 Average dry and wet diameter measurements and swelling ratio of the microthread types. * 
p<0.001, ** p<0.0001, n=8 microthreads ........................................................................................... 44 
Table 6 Mean ultimate tensile strengths of the ECM-fibrin microthread types. (n=32, n=33, n=33, n=25)
 ............................................................................................................................................................ 46 
Table 7 Mean strain at failure (mm/mm) for the ECM-fibrin microthread types. (n=29, n=30, n=32, n=24)
 ............................................................................................................................................................ 47 
Table 8 Mean elastic modulus (MPa) for each of the ECM-fibrin microthread types. *p<0.05, (n=29, 
n=33, n=32, n=21) ............................................................................................................................... 48 
Table 9 Average number of cells seeded on each ECM-fibrin suture type as determined through a 
CyQuant cell proliferation assay. (n=15 sutures) ................................................................................ 63 
  
10 
 
Chapter 1: Introduction 
 This project investigates the incorporation of native decellularized rat cardiac extracellular matrix 
(ECM) into fibrin microthreads and the effect that ECM incorporation has on the attachment of human 
mesenchymal stem cells (hMSCs) onto sutures for use in delivery to the infarcted heart. This project also 
investigates the effect that ECM incorporation will have on endothelial progenitor cell outgrowth. 
Previous work in the Gaudette lab shows that fibrin sutures can act as a delivery mechanism for hMSCs to 
infarcted myocardium [1]. This chapter serves as a review of the cardiac anatomy, the effects of infarction 
on healthy cardiac tissue, a summary of the current treatments of myocardial infarctions (MI), and an 
introduction of the extracellular matrix and its potential applications.  
Chapter 2. Background  
2.1 Myocardial Function and Myocardial Infarction 
The heart is a pump that circulates oxygenated and nutrient rich blood throughout the whole 
body. In the heart, there are four chambers: the right atrium, the right ventricle, the left atrium and the 
left ventricle. These four chambers are made of cardiac muscle, also known as myocardium. The inner 
surface of the myocardium is known as the endocardium while the outer surface is the epicardium [2]. 
The flow of blood begins when deoxygenated blood is received by the right atrium from the superior vena 
cava. The right atrium contracts and pumps blood into the right ventricle which then sends the 
deoxygenated to the lungs through the pulmonary artery where it becomes oxygenated. The newly 
oxygenated blood then enters the left atrium through the pulmonary vein. The blood is then pumped into 
the left ventricle and forced out into the aorta where is it circulated throughout the whole body [3]. After 
circulating through the body, the blood enters the superior vena cava and the process repeats. The left 
ventricle acts as the final pump to bring the blood to the entire body leading to it having thick muscle and 
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exhibiting the highest internal chamber pressure. The contraction of the heart is controlled through gap 
junctions that propagate action potentials across the myocardium [4, 5]. 
The myocardium is fed nutrients and oxygenated blood through coronary circulation. If a portion 
of the coronary circulation becomes blocked, the contractile muscle cells of the heart, or cardiomyocytes, 
are starved of oxygen and nutrients. This causes metabolic and physiological changes to occur within the 
heart [6, 7]. A non-continuous flow of oxygen and glucose to the myocardium causes adenosine 
triphosphate (ATP) production to switch from the aerobic pathway to the anaerobic pathway. Less ATP is 
produced causing the contractions of the heart to be weaker. The ATP production continues to slow as 
creatine phosphate reserves become used up. If myocardial ischemia continues, hydrogen ions, an 
anaerobic respiration byproduct, accumulates causing the intracellular pH to decrease [6].  
The pH imbalance causes osmotic flooding of cardiomyocytes and edema, thus causing 
permanent damage to the myocardium. Following these changes, a natural inflammatory response will 
occur.  Monocytes, neutrophils, and macrophages will migrate to clear the area of the damaged tissue 
and cells. Fibroblasts will also infiltrate the area and deposit fibrous collagen. These events create and 
further expand the infarct [8].  
Cardiovascular disease (CVD) is currently the leading cause of global deaths, accounting for 17.3 
million deaths per year, a number that is expected to grow to 23.6 million by 2030 [9]. One of the most 
prevalent forms of CVD is myocardial infarction (MI). Every year in the United States, approximately 
720,000 people suffer from and MI. Of these, early 515,000 cases are first time MIs and 205,000 are 
recurring MIs in people who have already experienced one or more MIs [10]. When a MI occurs, 
approximately one billion cardiomyocytes can be affected, which decreases the workload of the heart 
[11]. This nonfunctioning scar tissue that forms from the MI inhibits the heart’s ability to contract. This 
can lead to the development of heart disease. In 2010, over one million patients were diagnosed with 
heart failure, or the inability to sufficiently pump blood throughout the body, following a MI. Heart failure 
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can alter a patients’ ability to perform daily activities and tasks that require even minimal physical exertion 
[12].  
2.2 Clinical Treatments 
The regenerative capability of the heart is extremely limited and following an MI, the heart cannot 
repair itself. Thus, in order to repair the heart following an MI, medical intervention is required. 
Ultimately, the only way to cure irreparable heart failure developed from an untreated MI is a total organ 
replacement. However, transplantation inherently has many drawbacks. The odds of a heart being 
available for transplant is 3.5 in every 1000 deaths, or approximately 2000 hearts available each year. This 
poses a problem as the number of patients on the heart transplant waitlist is above or equal to 3,000 on 
any given day. Even for those lucky enough to receive a transplant, the risk of organ rejection post-
operation is high. While the first year survival rate of heart transplants is 88%, the main cause of death is 
infection due to the rejection of the donor heart. The percentage of patients developing acute rejection 
increases from 23% in the first year after operation to 45% in the fifth year after operation [13]. Because 
of the limited ability of organs available for transplant and the risk of rejection, clinical therapies have 
been developed to treat heart failure and even potentially regenerate the necrotic tissue developed from 
a MI.  
If a MI is left untreated, scar tissue formation will occur and can change the dimensions of the left 
ventricle and can cause ventricular wall thinning [14]. As infarct size increases, the ejection fraction, or 
amount of blood contained within the left ventricle that is ejected with each heartbeat, decreases [14]. In 
order to maintain normal cardiac output and stroke volume, the contractile pattern and length of the 
uninjured myocardium changes, often called compensatory responses, and increases the risk of 
ventricular aneurysm and rupture [14]. 
Current treatments for MI are aimed at treating the symptoms and effects of the infarction, but 
do not heal the infarct zone itself. These treatments include coronary bypass and ventricular remodeling. 
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Coronary bypass is a revascularization procedure that is used to restore blood flow to the myocardium 
[15]. Coronary artery bypass grafting (CABG) uses a blood vessel to redirect the blood flow around the 
infarction site and restore blood flow to the ischemic area. This treatment however does no regenerate 
cardiomyocytes or restore function of the collagenous scar tissue [15].  
Ventricular remodeling is used to reshape the heart by either a direct linear closure or an 
endoventricular patch plasty [16]. For a direct linear closure, a surgeon will reshape the heart by removing 
the infarcted region and suturing the heart back together. Depending on the infarct size, there may be an 
insufficient amount of healthy tissue to close the hole created by removing the infarcted region. Because 
of this, when closing, the surgeon may need to use a synthetic patch to close any remaining gaps in the 
ventricular wall [17]. This procedure restores the original dimensions of the heart and restores the internal 
pressure of the ventricle [17]. 
In the event that the infarcted region is too large to be safely removed, an endoventricular patch 
plasty is the preferred method for ventricular remodeling. The patch, which is anchored to the ventricular 
wall, can either be synthetic or autologous tissue. A surgeon will place the patch over the infarcted site 
and suture it in place. During this procedure, the infarcted region could be removed and the patch could 
be used to close the hole left behind [17]. 
The patches used in both of these methods, restore the volume of the ventricle and prevent 
shrinking of the heart [17, 18]. The synthetic materials commonly used for the patches, polyethylene 
terephthalate (PET, or commercially known as Dacron) ad polytetrafluoroethylene (PTFE) are inert and 
possess mechanical properties that are much stronger than native cardiac tissue [19]. The difference in 
mechanical properties causes fibrotic tissue to develop in the regions where native heart tissue meets the 
implant, and so, even with this procedure, scar tissue formation can reoccur and develop into large regions 
of fibrosis [19]. 
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2.3 Cellular Therapies for Tissue Regeneration 
Cellular therapies have been developed to regenerate function of tissue that has been damaged 
by injury or disease. Specifically, in cardiac regeneration, cell therapies are aimed at restoring the original 
function of the myocardium as opposed to removing the infarct as done in previously mentioned 
treatments. Cell types that have been used to restore myocardium during cellular therapies include bone 
marrow stem cells, skeletal myoblasts, embryonic stem cells, cardiac stem cells and fetal cardiomyocytes 
[20-23]. Most of the cell types however, present drawback that make them less than appealing for use in 
cellular therapies. Skeletal myoblasts, for instance, lack the capability to electrically couple with 
myocardium tissue and have been shown to cause fibrillation. Embryonic stem cells present the potential 
for tumor formation, cardiac stem cells have controversial existence, and fetal cardiomyocytes lack the 
ability to be obtained in sufficient numbers [20-23]. With the issues regarding these cell types, bone 
marrow stem cells, specifically human mesenchymal stem cells (hMSCs), are left as the most promising 
cell type for cardiac repair [24-26]. 
2.3.1 Mesenchymal Stem Cells for Cardiac Repair 
 Derived from adult bone marrow, hMSCs are adherent, multipotent cells that have the ability to 
differentiate into bone, cartilage and fat [28]. hMSCs have many characteristics that make them appealing 
for use in regenerative medicine including, ease of isolation, high expansion potential in vitro, and genetic 
stability [27-29]. In cardiac regeneration, hMSCs can induce angiogenesis, or the formation of new blood 
vessels, can be used allogenically without immune response, and can differentiate into a cardiomyocyte-
like phenotype [24, 28, 30]. When delivered into the heart, hMSCs have been shown to improve the 
cardiac function by reducing the infarct size and increasing the ventricular pressure [31-36].  
 Intramyocardial (IM) cell injections have been used as a method for cell delivery to improve 
cardiac function following a MI. However, there are several limitations that are associated with IM 
injections such as low cellular engraftment and retention, poor cell localization, low cell survival and the 
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lack of a matrix for cell adhesion [12, 24-26, 37]. In order for cellular therapies to be successful in the 
regeneration of myocardium, the delivery method must be improved.  
 Several studies have investigated the engraftment of hMSCs following IM injections. A study 
performed by Hou et al. delivered radiolabeled peripheral blood mononuclear cells (PBMNCs) using an 
intramyocardial (IM) injection, an intracoronary (IC) injection or an interstitial retrograde coronary venous 
(IRV) method into a pig model. Six days following induced myocardial ischemia by balloon occlusion for 
forty-five minutes, 10 million 111 indium-oxine-labeled human PBMNCs were delivered via IC, IM, or IRV 
injections. One hour after cell deliver, animals were euthanized and organs were harvested for assessment 
of cell distribution using gamma ray emission counting. The results of this study concluded that the 
majority of cells delivered were not retained by the heart. Cell retention for the IM injection was 11 ± 3%, 
IC injection was 2.6 ± 0.3%, and IRV injection was 3.2 ± 1%. It was found that many of the cells intended 
for delivery of the heart became entrapped in other organs including the lungs, liver, and spleen [38]. 
 In a similar study performed by Guyette et al, IM injections were used to deliver 100,000 quantum 
dot loaded hMSCs into an infarcted rat heart. Following one hour post injection, animals were euthanized 
and the hearts were harvested. The hearts were then fixed and cryosectioned to quantify the amount of 
engrafted hMSCs. The results showed an 11.8 ± 6.2% engraftment rate of cells when delivered via IM 
injection [39].  
 These two studies showed that when injecting a liquid cellular suspension into contracting heart 
muscle, a resulting high percentage of cell leakage out of the heart occurs. This is partially due to the 
heart’s contraction and the puncture hole created by the needle during injection [12, 37]. This liquid 
suspension, either of phosphate buffered saline or media, does not provide a proper matrix to aid in cell 
attachment and thus successful delivery [25, 26, 40]. Because of this, there is a need for an effective 
delivery mechanism to deliver hMSCs into a heart to regenerate infarcted tissue following an MI.  
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2.4 Fibrin  
2.4.1 Fibrin Scaffolds for Tissue Engineering 
Fibrin is a biopolymer that is naturally occurring in the body that has been used as a biomaterial 
for tissue regeneration. Fibrin is created in the body following a series of coagulation reactions that are 
triggered by platelet adhesion following an injury. This platelet adhesion initiates the production of 
thrombin, a protease which has the ability to cleave fibrinogen. Fibrinogen is a blood protein that when 
cleaved by thrombin, forms fibrin. When these two come together to form fibrin, the fibrin becomes 
insoluble and stops bleeding at a wound site and further promotes healing [41].  
The provisional matrix formed by fibrin in the body aids in the wound healing proves by providing 
a scaffold for cell adhesion, migration and infiltration [41]. Cell adhesion is promoted onto fibrin due to 
the fact that fibrin contains the protein sequence arginine-glycine-aspartic acid (RGD), a known ligand that 
promotes cell adhesion. Other benefits of fibrin include the advantage of being able to be produced from 
autologous fibrinogen and thrombin, its natural growth factors that it contains, as well as its Food and 
Drug Administration (FDA) approval for use as clinical glues and sealants [42-44].  
Fibrin is a versatile biopolymer and can be used in various forms in tissue engineering applications. 
Fibrin hydrogels are a popular form for tissue engineering and can be used for applications including 
adipose, cardiovascular, ocular, muscle, liver, skin, cartilage, neural, and bone tissues [45]. In order to be 
successfully used for these applications, fibrin hydrogels can be combined with different polymers 
(polyurethanes, polycaprolactones, polycaprolacton-based polyurethanes, b-tricalciumphosphates, etc.) 
to create customizable mechanical, surface, and degradation properties [45]. As stated previously, fibrin 
had been FDA approved to be used as a glue or sealant. Fibrin glues can be used for a wide range of 
applications including bone, cartilage, cornea, heart, blood vessel, tendon, and ligament regeneration 
[45]. As a glue, it is used to seal or adhere tissues, reduce blood loss during surgical procedures, accelerate 
healing, as well as protect against infection [46]. Fibrin glues have also been shown to be used as scaffold 
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matrix for the delivery of cells to a tissue to promote regeneration [47-49]. In any form, a fibrin scaffold 
can be coated with extracellular matrix proteins, such as fibronectin, vitronectin, laminin, and collagen, 
to enhance biological activity and cellular adhesion [50]. 
2.4.2 Fibrin Microthreads 
With the known advantageous uses of fibrin for tissue engineering, a fibrin extrusion process was 
developed at WPI [51]. Fibrinogen and thrombin are co-extruded to form fibrin microthreads. These 
threads can then be bundled and formed together to form one large diameter thread. This thread can 
then be used to create fibrin biological sutures. These sutures have been sown to be an effective scaffold 
for the delivery of human mesenchymal stem cells (hMSCs) into the heart. In the study by Guyette et al 
mentioned previously, hMSCs were delivered using fibrin sutures. This delivery mechanism exhibited a 
cell engraftment rate of 63.6±10.6%, a significant increase when compared to the IM injection group at 
11.8±6.2 % cell engraftment [39]. The fibrin suture delivery mechanism not only shows an increased 
engraftment rate of cells delivered into the heart, but also had a more localized delivery when compared 
to IM injections. 
Despite this improved engraftment rate of cells, the initial density of cells seeded onto the sutures 
remains low. During seeding, 100,000 hMSCs are delivered to the fibrin sutures and allowed 24 hours for 
cell attachment. However, after the 24 hours, approximately only 10,000 hMSCs are seen to adhere to 
the sutures [52]. The number of cells adhered onto the sutures could be increased using different methods 
such as increasing the cell density delivered to the sutures for seeding, increasing the seeding time above 
24 hours, or coating the sutures with adhesion proteins. If given the cell attachment percentage remains 
the same while seeding (10%), increasing the number of cells delivered to the suture would result in a 
higher number of cells still being wasted, or not adhering to the suture. This makes this approach 
unfavorable.  
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Increasing the culture time would allow hMSCs to proliferate on the suture, leading to a higher 
number of cells on the suture. Unfortunately, the problem with this approach is that hMSCs secrete 
fibrinolytic enzymes that would degrade the suture over a longer seeding period. This would create a 
weaker suture that would not have the mechanical strength needed to suture through the heart and 
deliver the hMSCs [53]. In a study by Coffin et al., 1 cm length fibrin biological sutures were seeded with 
50,000 cells in aprotinin supplemented media for time period of 1, 2, 3, and 5 days. The action of aprotinin 
on kallikrein leads to the inhibition of fibrinolysis. Aprotinin was proposed to decrease the fibrin suture 
degradation due to its properties of inhibiting proteases such as trypsin. The study showed that at the 
longer seeding time points (2, 3, and 5 days), the number of cells seeded onto the sutures increased with 
time. Mechanical testing of fibrin sutures cultured in aprotinin supplemented media also showed a higher 
elastic modulus and ultimate tensile strength than sutures cultured without aprotinin [54].  
The final method to potentially improve cell attachment onto fibrin sutures is coating the sutures 
with known adhesion proteins. By providing adhesion promoters into the fibrin or onto the fibrin suture 
surface, cellular attachment would increase. Materials used to increase cellular attachment and adhesion 
include extracellular matrix proteins such as collagen, fibronectin, laminin, and vitronectin [50]. In a study 
by Kowaleski et al., fibrin sutures that were coated in vitronectin showed an increase in cell adhesion, 
19,604±1.8929 cells, when compared to uncoated sutures, 6,821±739 cells [52]. 
2.5 Extracellular Matrix 
The tissues in the body are comprised of cells living within the extracellular matrix (ECM). The 
ECM provides not only structural and mechanical support for cells in vivo, but also play a very important 
role in function. As seen in Figure 1, the ECM comprises of a mixture of proteins, polysaccharides, 
glycoproteins, and growth factors that are in varying ratios depending on the tissue type, function, and 
overall health which impacts the protein composition as well as the mechanical properties of the tissue 
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[55]. The differing compositions give the ECM of a tissue a specific stiffness. This stiffness has been shown 
to affect cellular biochemical signaling [56]. 
 
Figure 1 Diagram of the Extracellular Matrix [57] 
2.5.1 Proteins of the Extracellular Matrix 
Cellular adhesion onto the ECM is signaled by the proteins that are present. The most abundant 
proteins found within the ECM in vivo are collagens, laminins, and fibronectins. Depending on the tissue 
function, location, and structure, these proteins come in varying concentrations. Aside from these 
proteins, there are smaller protein fractions that are found for specific tissue types.  
Collagen is the main structural protein found within the ECM and is found in different connective 
tissues in the body, making it the most abundant protein in the body. Between 25 and 35 percent of the 
total body protein is comprised of collagen and it makes up around three quarters of the dry weight of 
skin [58, 59]. Collagen is made of a bundle of three parallel, left-handed polyproline II-type helices formed 
together in a triple helix that typically has two identical 𝛼1 chains and an additional different 𝛼2 chain 
[59]. Collagen’s amino acid sequence consists of repeating amino acid sequences of either glycine-proline-
X or glycine-X-hydroxyproline where X is any other amino acid other than glycine, proline or 
hydroxyproline. This amino acid structure makes collagen easily identifiable as well as allows for the 
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variety of 𝛼1 and 𝛼2 chains which produce many different types of collagen [60]. Currently, there have 
been 28 different types of collagen that have been identified with the major collagen types being collagen 
I, II, III, IV, and V [61]. Of these types, collagen I is the most common collagen type and is the primary 
structural collagen in mammalian tissues. Collagen I provides mechanical support and stability of tissues 
[58]. Cell attachment to collagen is supported through specific binding sites and integrins [62].  
Laminins are a group of proteins found in the ECM that comprise the basal membrane of the ECM. 
They are trimeric proteins, meaning it is formed by three chains: an 𝛼 chain, a 𝛽 chain, and a 𝛾 chain. The 
chain composition determines the name of the laminin [63]. With this nomenclature, there have been 
fifteen varieties of laminins identified. The three trimeric proteins that make up the laminin form a cross-
like structure which allows for binding to cell membranes and other laminin chains to form a laminin sheet 
[64]. Laminin has been proven to be an important integrin for binding sites for cells and that lack of laminin 
production caused by genetic defects can be lethal [65].  
Fibronectin, as stated previously, is another prominent protein found in the ECM. The structure 
of fibronectin is dimeric and consists of identical monomers that are linked by disulfide bonds [66]. Within 
the body, there are two main types of fibronectin, one a soluble protein and the other an insoluble 
protein. The soluble protein version is a major protein component in blood plasma which is produced by 
hepatocytes. The insoluble protein version is found in the ECM and is secreted mostly by fibroblasts. The 
main role of this insoluble fibronectin is aiding in cellular attachment, migration, growth, and 
differentiation [66]. Cell adhesion to fibronectin is done through the integrin 𝛼5𝛽1 binding the repeating 
amino acid sequence RGD [67].  
2.5.2 Integrin Binding 
 The binding between cells and the extracellular matrix requires transmembrane cell adhesion 
proteins to link the matrix to the cytoskeleton of the cell. While some transmembrane proteoglycans have 
been shown to act as co-receptors for matrix components, the primary receptors for mammalian cells for 
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binding are the integrins. Integrins also play a role in cell-cell adhesion for blood cells [68]. Integrins are 
transmembrane obligate heterodimers, meaning they consist of two subunits: an 𝛼 (alpha) and a 𝛽 (beta). 
In mammals, there have been eighteen 𝛼 subunits and eight 𝛽 subunits that have been discovered [69]. 
In total, there have been twenty-four heterodimers that have been identified [70]. Integrins form across 
the cell membrane and act as the main contact between the cell cytoskeleton and the ECM. Specific 
integrins have been shown to bind to certain proteins as shown in Table 1 below.  
Table 1 Integrin-Ligand Binding Specificity [71] 
Integrin Protein 
𝜶𝟏𝜷𝟏 Collagens, Laminins 
𝜶𝟐𝜷𝟏 Collagens, Laminins 
𝜶𝟑𝜷𝟏 Laminins 
𝜶𝟒𝜷𝟏 Fibronectin 
𝜶𝟓𝜷𝟏 Fibronectin 
𝜶𝟔𝜷𝟏 Laminins 
𝜶𝟕𝜷𝟏 Laminins 
𝜶𝒗𝜷𝟏 Vitronectin 
𝜶𝒗𝜷𝟑 Vitronectin, 
Fibronectin 
𝜶𝒗𝜷𝟔 Fibronectin 
𝜶𝒗𝜷𝟖 Fibronectin 
𝜶𝟔𝜷𝟒 Laminins 
 When integrins are expressed, they are in a bent structure. It has been postulated that integrins 
are always bent however evidence has indicated that this bent manner is only observed when the 
integrins are inactivated. Integrins are activated when the cytoskeleton protein talin primes the integrin 
by binding to the β subunit and causing a conformational change in the integrin structure to go from bent 
to fully extended [72]. Once the integrin is activated, binding between the ligands from the ECM and the 
integrin can occur.  
2.5.3 Growth Factors 
 Growth factors are naturally occurring substances that are able to signal cellular processes such 
as growth, proliferation, migration, differentiation as well as a variety of other processes. Growth factors 
act as signaling molecules between cells as well as the matrix in which the cells are present. Common 
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growth factors include vascular endothelial growth factor (VEGF) and the family of fibroblast growth 
factors (FGFs). VEGF is a potent angiogenic factor that is essential to angiogenesis as well as plays an 
important role for the cardiovascular system. VEGF expression has been shown in cardiac myofibroblasts 
which play a major role in the repair of tissue following an infarction [73]. 
 Fibroblast growth factors are a family of growth factors that play roles in a variety of tissues and 
contribute to cell proliferation, differentiation and survival. In cardiac tissue, FGF has been shown to be 
upregulated following a cardiac injury, such as an infarct, and contribute to tissue remodeling [74]. 
Following tissue decellularlization, these growth factors remain within the extracellular matrix along 
with the other proteins and ECM components. The growth factors present in the decellularized ECM 
attribute to the success ECM based scaffold applications [75].    
2.5.3 Extracellular Matrix Based Scaffolds  
 The promising properties of ECM have encouraged the development of biological scaffold 
materials composed of ECM derived from varying tissues. These ECM scaffolds have been shown to 
facilitate remodeling of many tissues in preclinical animal studies and in human clinical applications. The 
ECM used in these scaffolds can be derived from various tissue types including skin [76], heart valves [77-
83], nerves [84, 85], blood vessels [86-89], small intestinal submucosa [90-92], tendons [93], ligaments 
[94], and skeletal muscle [95]. These tissues are also derived from multiple species such as humans, pigs 
(porcine), cows (bovine), and even horses (equine).  
 The ECM is comprised of a convoluted mixture of molecules arranged in a specific three-
dimensional (3-D) pattern that determines structural and biological properties of a tissue. As a scaffold, 
the ECM is biodegradable, unless processed in a way that forms unbreakable crosslinks between 
molecules.  These two properties; the complex structure and in vivo biodegradability, have proven to show 
positive effects in the process of remodeling that determines clinical outcomes.  
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 Right now, there are a number of commercially available ECM-based scaffold products that have 
been used in a clinical setting that prove the advantageous aspects of using ECM to repair diseased or 
damaged tissues. These products include porcine and bovine derived heart valves for human heart valve 
replacement, decellularized and crosslinked human dermis (Alloderm, Lifecell) and chemically crosslinked 
purified bovine type I collagen (Contigen, Bard, Inc.). Other products have been used for skin, cartilage, 
bone, and nerve tissue repair and regeneration. 
2.5.4 Extracellular Matrix Based Treatments for Cardiac Repair 
In addition to the commercially available ECM products, many experimental studies have been 
conducted to explore other areas of application for ECM based treatment. As mentioned previously, the 
ECM from many different organs can be used to regenerate tissues and cells in vivo. While the ECM from 
any organ is comprised of many of the same proteins and molecules, each organ has a unique composition 
or proteins and other molecules that provides a tissue specific microenvironment for the resident cells. In 
a study by Sullivan et al. the extracellular matrix of a rat heart was characterized in a healthy state as well 
as in an infarcted state at different time points. A healthy heart is composed of several proteins including 
collagen I, collagen VI, laminin and fibronectin. This composition creates a unique microenvironment that 
is able to guide cell proliferation and differentiation into a cardiac lineage [96].  
Many studies have explored the effects that cardiac ECM has on cellular events. In a study by 
Singelyn et al., a decellularized cardiac ECM based hydrogel was created and evaluated in both in vitro 
and in vivo experiments. First, the cardiac ECM hydrogel was incubated with cardiomyocytes and 
evaluated for cell survival and attachment for up to 5 days. The results were compared to cardiomyocytes 
cultured on collagen coated dishes and collagen gels.  It was found that the cells were able to survive on 
the ECM hydrogel for up to 5 days. The cardiac ECM hydrogel was also evaluated in a vascular cell 
migration assay. A Chemotaxis 96-well Cell Migration Assay Kit was used to evaluate the attraction of 
human coronary artery endothelial cells (HCAECs) and rat aortic smooth muscle cells (RAMSCs) toward 
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the cardiac ECM hydrogel. The results were compared to a migration assay of the cells toward collagen, 
fetal bovine serum and pepsin. The migration assay revealed that the RAMSC migration was significantly 
increased when migrating toward the cardiac ECM hydrogel. The migration of the HCAECs followed this 
same trend of an increased migration toward the cardiac ECM hydrogel. The results of this experiment 
showed that the matrix was able to promote migration of vascular cells [97].  
Following the in vitro study, the researchers performed an in vivo study where they injected the 
cardiac ECM hydrogel into the left ventricular wall of rats. The hearts were evaluated at a short term 4-
hour time point and a long term 11-day time point. Following immunohistochemical staining for 
endothelial cells and smooth muscle cells, the researchers saw significant infiltration of both cell types 
within the matrix region at 11 days. The 4-hour time point was revealed to be too early for the evaluation 
of cell infiltration into the matrix [97].  
Another study performed by French et al., sought to explore the effects that cardiac ECM has on 
cardiac progenitor cell (CPC) function in vitro. Cells were isolated from adult male rats and were cultured 
in different matrices. The culture conditions consisted of coating tissue culture plates in either cardiac 
ECM or Collagen I (COL) isolated from rat tails. Following culture, the CPCs were analyzed for gene 
expression during cardiogenic differentiation using quantitative PCR transcription. The results of this 
experiment suggested that the cells seeded onto the cardiac ECM demonstrated an enhanced 
differentiation toward the cardiac lineage and a decreased maturation toward a fibroblastic lineage.  
Western blots were also performed on protein samples taken from CPC culture media under the ECM and 
COL conditions after 7 days. The data from the western showed that CPCs cultured on cardiac ECM had 
significantly higher levels of Gata-4 and Nkx2.5, known cardiomyocyte markers, when compared to the 
cells cultured on COL [98].  
 This study performed many other assays on the CPCs cultured on cardiac ECM and COL including 
assays for proliferation, survival and adhesion. These experiments revealed many findings. First, the 
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proliferation assay showed that after 48 hours of cell culture on the cardiac ECM, the CPC had a significant 
increase in proliferation when compared to those seeded on COL. The survival assay, which consisted of 
an Annexin V stain performed after 12 hours of CPC culture in serum starved media, showed a decrease 
in apoptosis for the CPCs cultured on cardiac ECM when compared to those cultured on COL. Finally, a 
microfluidic adhesion assay was performed under increasing levels of shear stress. The results of this 
experiment showed that CPCs cultured on cardiac ECM adhered more strongly as compared to those 
cultured on COL. This study shows that when CPCs are cultured on a 2-D culture plate coated with cardiac 
ECM, the cells have enhanced adhesion, maturation, proliferation and survival when compared to cells 
cultured on collage I alone [98].  
Cardiac ECM based materials have been shown to be used as successful platforms to increase the 
differentiation of progenitor cells into a cardiac lineage, promote cardiac cell proliferation and guide 
endothelial cell migration. These factors prove cardiac ECM to be a useful tool in cardiac regeneration as 
well as a potential tool to improve our fibrin microthread based biological sutures.   
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Chapter 3: Hypothesis and Specific Aims 
 We hypothesize that incorporating decellularized cardiac extracellular matrix into fibrin 
microthreads will enhance the potential as a stem cell delivery platform when microthreads are used in 
the form of a suture and will promote endothelial progenitor cell outgrowth.  
Specific Aim 1: Produce Fibrin-ECM microthreads, confirm ECM protein incorporation and examine the 
effect that ECM incorporation has on mechanical and structural performance of fibrin-ECM threads 
when compared to fibrin only microthreads. 
 Solubilized extracellular matrix derived from lyophilized decellularized rat hearts will be 
incorporated into fibrin microthreads during the microthread production process previously developed 
by Cornwell et al [51]. The ECM will be incorporated at concentrations of 0, 5, 10, 15, 20, and 30 µL of 
ECM per 1 mL of fibrinogen and thrombin. With increasing concentration of ECM, the crosslinking 
between fibrinogen and thrombin can be affected, leading to the structure and mechanical stability of the 
microthreads to change. Diameters of the ECM-fibrin microthreads will be measured to evaluate how 
microthread structure changes with increasing ECM incorporation. Microthread swelling capability will be 
determined by the ratio between wet thread diameter measurements and dry diameter measurements. 
Mechanical properties will be evaluated using single threads in a uniaxial tensile test. The elastic modulus, 
ultimate tensile strength, and strain at failure will be used to assess mechanical properties of the ECM-
fibrin microthreads. The data acquired from the diameter measurements as well as mechanical testing 
will be compared to data obtained from control fibrin microthreads.  
Specific Aim 2: Determine the effect of ECM protein incorporation on cell adhesion to fibrin-ECM 
sutures.  
If the extracellular matrix is the structure that provides cues for cellular adhesion, migration and 
differentiation in vivo, the incorporation of native ECM proteins into fibrin microthreads will inhibit cells 
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to adhere to sutures at a higher density. To determine the effect on cell attachment, 100,000 hMSCs will 
be seeded onto sterile ECM-fibrin sutures for 24 hours. Following seeding, sutures will undergo a Cyquant 
DNA Assay to count the number of cells adhered to the sutures as well as Hoescht and Phalloidin staining 
for visual confirmation of cell seeding.  
Specific Aim 3: Determine the effect of ECM protein incorporation on endothelial progenitor cell 
outgrowth.  
Cell outgrowth of endothelial progenitor outgrowth cells (EPOCs) will be evaluated to show the 
effect that the ECM incorporated into the fibrin presents. EPOCs will be plated into a 6-well plate at 10,000 
cells/cm2 and allowed to reach full confluency. A standard scratch assay will then be performed by 
scratching the plate surface with a 200uL micropipette tip down the approximate center of each well. In 
wells 1 and 2, a 15% ECM microthread will be placed within the scratch and weighed down so that it does 
not move. This will be repeated for fibrin microthreads in wells 3 and 4. Wells 5 and 6 will serve as control 
wells and will be left blank. The outgrowth in each well will be evaluated every 6 hours for 24 hours by 
obtaining images at four designated locations in each well. Following the 24-hour outgrowth, the average 
distance travelled of the cells will be determined from the images. Finally, the microthreads will be 
removed from the 6-well plate and will be stained with DAPI to determine if any cell attachment onto the 
microthreads occurred.   
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Chapter 4: Aim #1: Produce ECM Microthreads, Confirm ECM 
Incorporation and Test for Mechanical Properties 
4.1 Introduction 
 The purpose of this aim is to evaluate the effect that ECM has on the mechanical properties and 
structure of fibrin microthreads when incorporated at varying concentrations. Decellularized cardiac 
extracellular matrix will be solubilized into a homogeneous mixture and then incorporated into a fibrin 
microthread procedure previously developed by Cornwell et al [51]. Once ECM-fibrin microthreads are 
created in varying concentrations, they will be tested and evaluated for ECM incorporation confirmation 
through immunohistochemical staining for major cardiac ECM proteins and mechanical properties such 
as elastic modulus and ultimate tensile strength.  
 Our hypothesis is that the ECM solution will be successfully incorporated into fibrin microthreads 
when incorporated into fibrinogen and thrombin separately prior to solution mixing. Also, we hypothesize 
that by incorporating ECM into fibrin, the microthread diameters will decrease as ECM concentration 
within the microthreads increases. Lastly, we hypothesize that the microthread mechanical properties of 
elastic modulus and ultimate tensile strength will decrease with increasing ECM concentration.  
4.2 Methods 
4.2.1 Rat Heart Decellularization Process 
 All animal procedures were performed in accordance with the Institutional Animal Care and Use 
Committee at Worcester Polytechnic Institute and NIH Guide for the Care and Use of Laboratory Animals. 
Hearts were isolated from Sprague Dawley retired breeder adult rats following animal euthanasia with an 
intracardiac sodium pentobarbital injection. Hearts were stored in Dulbecco’s phosphate buffered saline 
(DPBS) (Corning) and frozen at -30˚C until ready to use. For decellularization, hearts were thawed and 
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transferred to a petri dish containing fresh DPBS. A perfusion-based decellularization process was 
unnecessary as the structure of the heart would not be kept intact during further processing. This lead to 
the choosing of an immersion-based decellularization process. To prepare the hearts for decellularization, 
they were minced into small pieces approximately 3mm x 3mm x 3mm.  
 Minced heart tissue of approximately four hearts was then placed into one 50 mL conical tube 
containing 25 mL of 1% sodium dodecyl sulfate (SDS; Sigma) in deionized (DI) water. The conical tubes 
were rotated on a Scilogex MX-T6-S rotator until tissue samples appeared translucent, approximately 1 to 
2 days with the 1% SDS solution being changed every 12 hours. Following SDS immersion, the heart tissue 
pieces were rotated in 25 ml 1% Triton-X 100 (Sigma) in DI water for 24 hours with the solution being 
changed once after 12 hours. The final step of the decellularization process was to clear the tissue in DI 
water for 24 hours, changing the DI water after 12 hours. This final step washed any remaining chemicals 
from the tissue sections.  
 Following the final step of decellularization, the DI water was removed from the conical tubes and 
the ECM pieces were re-suspended in approximately 10 mL of fresh DI water for storage. The conical tubes 
were then placed in a -80˚C and stored until tissue lyophilization. The decellularization process of the 
cardiac tissue is illustrated in Figure 2 below. A detailed procedure of cardiac decellularization can be 
found in Appendix A.1. 
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Figure 2 Left: Full hearts obtained from adult Sprague Dawley rats. Middle: Heart tissue minced into small pieces. Right: 
Decellularized cardiac tissue. 
4.2.2 Decellularized ECM Lyophilization 
 Decellularized heart tissue was lyophilized using an SP Scientific VirTis Benchtop Pro with 
Omnitronics lyophilizer (SP Scientific, Warminster, PA). Conical tubes containing frozen decellularized 
heart tissues in DI water were prepared for lyophilization. Briefly, the caps to the conical tubes were 
removed. Next, a KimWipe was placed over the opening of the conical tube and was secured tightly with 
tape. This is seen in Figure 3.  
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Figure 3 Decellularized ECM frozen in approximately 10mL of DI water prepared for lyophilization. 
The KimWipe will allow for the lyophilizer to pressurize the tubes while ensuring that no ECM is 
lost within the conical tube. Finally, the conical tubes were kept on ice until they were placed in the 
lyophilizer to ensure no premature thawing occurred.  
While the ECM samples were being prepared the VirTis lyophilizer was turned on and set to reach 
a temperature of -104.3˚C and a pressure of about 14 millitorr (mTorr). When the machine was ready, the 
conical tubes were placed in a glass chamber and vacuum sealed onto the machine. Samples were 
lyophilized until all ice crystals had been visually removed. This process could take between 12 hours and 
4 days, depending on the initial DI water volume within the conical tube. Lyophilized ECM samples were 
stored in a -80 °C freezer, to keep moisture out of the tissue, until ECM solubilization. Figure 4 below 
shows the decellularized ECM after it had been lyophilized. A detailed procedure of ECM lyophilization 
can be found in Appendix A.2.  
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Figure 4 Decellularized ECM has been lyophilized at -104.3°C and 14mTorr for approximately 48 hours 
4.2.3 Lyophilized ECM Solubilization 
Lyophilized ECM samples were obtained from a -80 °C freezer and placed on ice. ECM was ground 
into a powder using a mortar and pestle that had been stored at -80˚C to ensure that the lyophilized ECM 
did not thaw. Large-sized pieces of ECM needed additional cutting with iris scissors into smaller pieces for 
successful grinding.  
Extracellular matrix solubilization was performed using a previously defined protocol [99]. Briefly, 
10mg of porcine gastric pepsin (Sigma Aldrich) was dissolved in 10ml of 0.1M HCl. Then, 100mg of ground 
ECM was added to the solution and stirred using a magnetic stir plate. The original protocol called for 48 
hours of stirring however, upon inspection our ECM had not fully solubilized at 48 hours and so the 
solution was stirred until nearly full solubilization could be seen. It was found that after 5 days, the ECM 
was fully or nearly fully solubilized. After solubilization, the ECM solution was neutralized to a pH of 7.4 
with 1M NaOH and refrigerated for up to 1 week. The figure below, Figure 5, shows the ECM throughout 
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the process of solubilization. The final concentration of the solubilized ECM was 100mg/10mL or 
10mg/mL. A detailed procedure of lyophilized ECM solubilization can be found in Appendix A.3. 
 
Figure 5 Solubilization process of decellularized ECM. Left: 100mg of the lyophilized ECM is measured and placed into a glass 
scintillation vial. Middle: A solution of 10mg of pepsin and 10ml of 0.1M HCl is added to the ECM. Right: The ECM is fully 
solubilized following 5 days of constant stirring. 
4.2.4 ECM-Fibrin Microthread Co-Extrusion 
 ECM-Fibrin microthreads were co-extruded using solutions of fibrinogen and thrombin 
supplemented with ECM by altering a previously developed protocol for fibrin microthread extrusion [51]. 
Briefly, thrombin isolated from bovine plasma (Sigma, St. Louis, MO T4648) at a concentration of 40 U/ml 
was frozen at -20˚C as a stock solution; and diluted to a concentration of 6 U/ml in 40mM CaCl2 (200uL 
thrombin in 850uL of 10mM CaCl2) for extrusion. Fibrinogen (Sigma, St. Louis, MO F4753) was dissolved 
in HEPES buffered saline solution (HBSS, 20mM HEPES, 0.9% NaCl) at a concentration of 70 mg/ml and 
stored at -20˚C. Fibrinogen and thrombin aliquots were placed in room temperature water and warmed 
to 37˚C. Separately, approximately 1mL of the solubilized ECM solution was isolated from the stock 
solution and placed in a 1.7mL microcentrifuge tube. The ECM solution was then filtered using decreasing 
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sized hypodermic needles. First the ECM solution was filtered through an 18-gauge needle to remove 
larger insolubilized pieces of ECM. The ECM solution was then filtered through both 20-gauge and 22-
gauge needles in succession. Finally, the ECM solution was filtered through a 27-gauge needle to filter out 
any final ECM particles that could potentially clog the polyethylene tubing used during microthread 
extrusion. The filtered ECM was then placed in a separate 1.7mL microcentrifuge tube.  
 The fibrinogen and thrombin were then prepared with the incorporation of ECM at varying 
concentrations between 0 and 20 percent ECM (v/v). Briefly, for the 5% ECM microthreads, 950L of 
thrombin and fibrinogen were individually transferred to separate 1.7mL microcentrifuge tubes. Next, 
50L of the filtered ECM solution was added into the tubes and mixed thoroughly.  The thrombin and 
fibrinogen ECM solutions were then drawn up into separate 1mL syringes using 20-gauge needles. The 
needles were removed and the syringes were loaded and secured into a New Era 6-channel syringe pump 
(New Era Syringe Pumps, Farmingdale, NY). The thrombin and fibrinogen syringes were attached to the 
input ports on a FibriJet blending connector (Nordson Micromedics, Loveland, CO). Polyethylene (PE) 
tubing with an inner diameter of 0.38 mm (Scientific Commodities Inc, Lake Havasu City, AZ) threaded 
onto a 27-gauge needle was attached to the output port of the blending connector. The solutions were 
pumped at a rate of 0.23mL/min through the PE tubing into a room temperature bath of 10mM HEPES 
with 20mM CaCl2 buffer at pH of 7.4 and the microthreads were extruded using a hand-drawn technique. 
Following extrusion, the microthreads were kept in the HEPES bath for 15 minutes to allow for formation. 
The ECM-fibrin microthreads were then removed from the bath and hung horizontally across a cardboard 
box to air dry overnight. Other ECM-fibrin concentrations for microthread formation are shown in Table 
2. The procedure for ECM-fibrin microthread extrusion can be found in Appendix B. 
 
 
35 
 
Table 2 Volumes of ECM solution and fibrinogen and thrombin to make ECM-Fibrin microthreads. 
ECM Final Concentration by 
Volume 
Fibrinogen 
Volume 
Thrombin Volume ECM Volume in F and T 
10% 900µL 900µL 100µL 
15% 850µL 850µL 150µL 
20% 800µL 800µL 200µL 
30% 700µL 700µL 300µL 
 
 Using the concentrations of the individual microthread components as well as their concentration 
within each microthread type, we were able to calculate an overall fibrinogen, thrombin and ECM 
concentration in each microthread type. For example, in order to make the 5% ECM microthreads, 50uL 
of the ECM solubilized solution was added to fibrinogen and 50uL of the ECM solubilized solution was 
added to the thrombin. In order to add this 50uL to the fibrinogen and thrombin, the initial volumes of 
fibrinogen and thrombin were reduced by 50uL, or an overall 5%. Therefore, the final concentrations of 
fibrinogen and thrombin changed from their initial concentrations. The initial concentration of fibrinogen 
is 70mg/mL. When decreasing this by 5%, the concentration of fibrinogen is 66.5mg/mL. The initial 
concentration of thrombin is 6U/mL. When decreasing this by 5%, the concentration of thrombin is 
5.7U/mL. The initial concentration of ECM being added into the fibrinogen and thrombin is 10mg/mL. For 
the 5% ECM microthreads, a total of 100uL is used. Therefore, there is 1mg of ECM in the final 2000uL of 
fibrinogen and thrombin, or 0.5mg of ECM per 1000uL of fibrinogen and thrombin. Using the average 
number of threads produced per extrusion, we calculated the average amount of ECM within each thread. 
Table 3 below shows the values derived from the calculations to determine the final concentrations of 
fibrinogen, thrombin and ECM.  
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Table 3 The final concentrations of fibrinogen, thrombin and ECM calculated based on the final ECM solution volume for each 
thread type. 
Microthread Type Final Total Fibrinogen 
Concentration 
Final Total Thrombin 
Concentration 
Final Total ECM 
Concentration 
Fibrin 70 mg/mL 6 U/mL 0 mg/mL 
5% ECM 66.5 mg/mL 5.7 U/mL 0.5 mg/mL 
10% ECM 63 mg/mL 5.4 U/mL 1 mg/mL 
15% ECM 59.5 mg/mL 5.1 U/mL 1.5 mg/mL 
 
4.2.5 Immunohistochemical Staining for Cardiac Extracellular Matrix Proteins 
Once the microthreads were created, they were fluorescently stained for some of the major 
cardiac ECM proteins including Collagen I (Santa Cruz Biotechnologies, Dallas, TX), Fibronectin (Abcam, 
Cambridge, UK) and Laminin 111 (Abcam, Cambridge, UK) to confirm ECM incorporation. Similar to how 
samples for diameter measurements were prepared, a 2cm section of an individual microthread was 
secured to a glass slide using superglue. For each microthread type, 2 samples were prepared per stain so 
that one could be used for a negative control. Each stain was performed 4 times, making the total number 
of positive stained sampled per protein stain, 4.  
 The staining for proteins followed a general protocol to fix and stain for specific proteins. Briefly, 
the samples were rinsed in DPBS twice for approximately 5 minutes and then fixed in 4% 
paraformaldehyde (Fisher Scientific, Fair Lawn, NJ) in DPBS for 10 minutes. Samples were then washed 
two times again in DPBS and then treated with 0.25% Triton X-100 (Sigma Aldrich, St. Louis, MO) in DPBS 
for 10 minutes. Following two more DPBS washes, the samples were blocked in 1% bovine serum albumin 
(BSA) (Fisher Scientific) in DPBS for 45 minutes. Following blocking, the samples intended to show a 
positive signal were treated with the primary antibody for the protein of choice overnight. The samples 
intended for a negative signal were kept in 1% BSA in DPBS. The next day, all samples were washed in 
DPBS twice for 5 minutes each and treated with the secondary antibody of the protein of choice for 1 
37 
 
hour. Samples were then washed two final times in DPBS. Coverslip spacers were added and the sampled 
were sealed with CytosealTM 60 and then covered with glass coverslips. Table 4 lists the primary and 
secondary antibodies used for protein staining as well as the concentrations of each.  
Table 4 Concentrations for IHC protein staining for major cardiac proteins. 
Protein Primary Antibody Primary 
Concentration 
Secondary 
Antibody 
Secondary 
Concentration 
Collagen I Anti-Collagen I 
sc8783 
1:200µL in BSA Rabbit Anti-goat 
488 
1:400µL in BSA 
Fibronectin Anti-Fibronectin 
ab2413 
1:200µL in BSA Goat-Anti-Rabbit 
546 
1:500µL in BSA 
Laminin 111 Anti-Laminin 
ab11575 
1:100µL in BSA Goat-Anti Rabbit 
488 
1:500µL in BSA 
Stained thread samples were visualized and imaged on a Leica Upright DMLB2 fluorescent 
microscope at 20X magnification. Images were also taken on a Leica TCP SP5 confocal laser scanning 
microscope (Leica, Germany) for higher quality imaging and to assess the surface changes on the 
microthreads following ECM incorporation. Images were qualitatively assessed for protein fluorescent 
signal. A detailed procedure for the immunofluorescent protein staining can be found in Appendix C.  
4.2.6 Structural Analysis of ECM-Fibrin Microthreads 
 Fibrinogen is a fairly viscous fluid and it can be hypothesized that when adding the solubilized 
ECM, a much less viscous fluid, the resulting microthreads will have different structural properties than 
normal fibrin microthreads. To determine how the ECM affects the structure of fibrin, diameter 
measurements of the microthreads were taken for each type of ECM-fibrin microthread. A 3cm section of 
an individual microthread was cut and secured to a glass slide using Gorilla Glue® super glue. An image at 
three different locations on the microthread were obtained on Leica SM LB2 inverted microscope at 20X 
magnification. In order to get a representative diameter over the 3cm section, the first image was taken 
within the first centimeter of the thread, the second image was taken within the middle centimeter of the 
thread and the third image was taken in the final centimeter of the thread. The microthread sections were 
then hydrated in DPBS for 20 minutes. Following hydration, two drops of DPBS were placed on each 
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microthread and a glass coverslip was then laid across the microthread. Three images of each hydrated 
thread were taken again at 20X magnification in the same manner as the dry images. This was repeated 
so that each microthread type had 8 total representative microthread sections for diameter 
measurements.   
 Diameters were measured using the measuring feature in ImageJ software. Briefly, each image 
was loaded into the software for analysis. The image was scaled to ensure the measurements to be 
accurate: for 20X magnification: 376 pixels: 100µm. Once scaled, a line was drawn across the microthread 
from edge to edge to represent the true diameter of the thread. The length of the drawn line was then 
measured using the software. This was repeated so that 10 total measurements were taken per image. 
The measurements for each image were then combined with the measurements from the images of the 
rest of the microthread section. These 30 measurements were then compiled with the rest of the 
measurements for the microthread type so that all 240 measurements could be used for statistical 
analysis.  
 Diameter measurements were taken for all images of dry and wet microthreads. In the hydrated 
state, the microthreads were imaged in the same manner that the dry images were taken. This allowed 
us to have dry diameter measurements and wet diameter measurements that were taken for the same 
area on the microthread. Once all measurements were made, the swelling ratio between the wet and dry 
measurements was determined by dividing the individual wet diameter measurements by their 
corresponding dry diameter measurement. The swelling ratio of the threads is used to determine the 
potential that the threads will have to increase their surface area to attain maximum cell seeding in future 
experiments. For all measurements, standard deviations were determined as well using Excel.  
4.2.7 Tensile Testing of ECM-Fibrin Microthread Mechanical Properties 
 Mechanical testing was performed on an Instron E1000, using a 1N load cell. The samples were 
pulled to failure at a rate of 10mm/min. For each microthread type; fibrin, 5% ECM, 10% ECM, and 15% 
39 
 
ECM, six samples were tested using a strain to failure method. Each round of testing was performed 6 
times, making the total number of samples 36. Each sample consists of a four-centimeter section of a 
microthread that is attached to a mechanical testing construct made of vellum paper, cut into rectangles 
measuring 2cm x 4cm. In the middle of the construct, a 3cm long section has been cut out of the rectangle. 
The microthread sample was laid over this open space and secured on either end using medical grade 
silicone adhesive (Bluestar Silicones, Ventura, CA). The microthread construct can be seen in Figure 6. 
 
Figure 6 Microthread Mechanical Tensile Testing Constructs. 
Each testing sample will be taken from one single microthread to ensure the data collected is an 
accurate representation of the microthread type. The testing constructs were left overnight to allow the 
silicone adhesive to fully cure.  
In preparation for mechanical testing, each construct was hydrated in Dulbecco’s phosphate 
buffered saline (DPBS) for 20 minutes. Each sample was imaged for hydrated diameter measurements as 
described previously in section 4.2.6. The average diameter for each thread will be used to calculate the 
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original cross sectional area to then accurately determine the ultimate tensile strength. The construct was 
then loaded on to the Instron and secured using custom modified steel alligator clips seen in Figure 7. 
 
Figure 7 Modified Steel Alligator Clips for Microthread Tensile Testing. 
The microthreads were continuously hydrated using DPBS from a dropper until the test began. 
Upon the start of the test, the vellum paper construct was cut to allow for tensile pulling and the 
microthread was pulled taught, in case the microthread was drooping slightly between the grips. Once 
the microthread was completely loaded, the length was measured in order for accurate calculations of 
the ultimate tensile stress and strain.  
Using Bluehill software, a tensile test to failure was performed on each microthread. Microthread 
diameter and initial microthread length between the grips was input into the Bluehill software for 
calculations and the test was started. The data output by the Bluehill software was in Force (N)/ 
Displacement (mm). Using the measured diameter and length of the microthread, the Force-Displacement 
was converted to Stress-Strain and plotted. Finally using a MatLAB code, the stress-strain curve was used 
to determine the Ultimate Tensile Strength (UTS), Elastic Modulus (E), and Strain at Failure (SAF). Other 
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parameters calculated were Plastic Modulus and Yield Strength, however these parameters were not used 
for statistical analysis. 
4.2.8 Statistical Analysis 
All results are presented as mean ± standard deviation. Individual data points are represented 
graphically in a vertically aligned scatter plot. The diameter measurements and mechanical testing 
parameters were first analyzed to remove data point outliers. For diameter measurements, a computer 
calculation was used to determine outliers. For mechanical testing measurements, two round of data 
analysis was used to remove outliers. First, samples were removed from further data analysis if they 
experienced failure at the grips. Secondly, the data points for each mechanical parameter were analyzed 
using a computer calculation to remove further outliers. The results were then compared using an 
ordinary one-way ANOVA test. The statistical significance for the diameter comparisons was determined 
as p<0.0001. The mechanical statistical significance was determined as p< 0.05. 
4.3 Aim 1 Results 
4.3.1 Immunohistochemical Staining Results 
 Microthreads of varying ECM-fibrin concentrations were stained for major cardiac proteins 
including Collagen I, Fibronectin, and Laminin 111. Following the staining, the microthreads were imaged 
using a fluorescent microscope to qualitatively assess the incorporation of ECM into the fibrin as well as 
a confocal microscope to assess microthread surface changes with the inclusion of ECM. The figures below 
show the inverted microscope and confocal microscope images of the microthreads after being stained 
for the proteins collagen I (Figure 8), laminin 111 (Figure 9) and fibronectin (Figure 10). The fluorescent 
images taken using the inverted microscope (Figures 8 A, 9 A, and 10 A) show that when compared to 
normal fibrin microthreads, the ECM-fibrin microthreads exhibit the fluorescent signal when the major 
cardiac proteins are present. The control fibrin microthreads does not exhibit this signal, suggesting that 
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these proteins are not present in the fibrin microthreads but become present when the solubilized ECM 
is incorporated during the extrusion process. The images taken using a confocal microscope (Figures 8 B, 
9 B, and 10 B) show the effect that ECM incorporation has on microthread surface topography. As seen, 
the surface topography of the microthreads visibly changes as the ECM incorporation concentration 
increases.  
 
Figure 8 Immunofluorescence of ECM-fibrin microthreads that had been stained for Collagen I. A. Inverted fluorescent 
microscope images of the microthreads. B. Confocal microscope images of the microthreads. Scale bar=100um 
Fibrin 10% ECM 15% ECM  5% ECM 
5% ECM 10% ECM 15% ECM 
A 
B 
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Figure 9 Immunofluorescence of ECM-fibrin microthreads that have been stained for Laminin 111. A. Inverted fluorescent 
microscope images of the microthreads. B. Confocal microscope images of the microthreads. Scale bar=100um 
 
Figure 10 Immunofluorescence of ECM-fibrin microthreads that have been stained for Fibronectin. A. Inverted fluorescent 
microscope images of the microthreads. B. Confocal microscope images of the microthreads. Scale bar=100um 
Fibrin 10% ECM 15% ECM  5% ECM 
5% ECM 10% ECM 15% ECM 
A 
B 
Fibrin 10% ECM 15% ECM  5% ECM 
A 
5% ECM 10% ECM 15% ECM B 
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4.3.2 Microthread Diameter Results 
 Diameter measurements of the ECM-fibrin microthreads were used to determine the effect that 
ECM incorporation can have on structural properties of fibrin microthreads. Following microthread 
extrusion, the ECM-fibrin microthread types underwent measuring of their dry and wet diameters using 
microscope imaging and ImageJ software. The diameters determined from the dry and wet threads were 
also used to determine the swelling capability of the threads. Table 5 below shows the average diameters 
of the varying types of ECM-fibrin microthreads in their natural dry state as well as after being hydrated 
for 20 minutes. The average swelling percentage is also shown in the table.  
Table 5 Average dry and wet diameter measurements and swelling ratio of the microthread types. * p<0.001, ** p<0.0001, n=8 
microthreads 
 5% ECM 10% ECM 15% ECM FIBRIN 
DRY DIAMETER 
(UM) 
71.4±14.3* 51.9±15.1 65.6±25.9 88.8±18.8** 
WET DIAMETER 
(UM) 
157.2±38.1** 124.4±42.8 145.3±59.3 195.7±75.9** 
SWELLING RATIO 
(%) 
219.6±26.9 231.9±50.0 225.7±39.6 224.5±82.6 
Figure 11 graphically shows the values in Table 5 as a comparison of the diameters of the ECM-
fibrin microthreads when dry and wet. The dry diameters of the microthreads decrease with increasing 
ECM concentration with the exception of the 15% ECM microthreads when compared to the 10% ECM. 
However, overall the diameters of the microthreads that have ECM incorporated into them have 
diameters that are significantly less than that of the fibrin only microthreads. The wet diameters follow 
this same trend as well. 
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Figure 11 Comparison of average Right: dry diameters and Left: wet diameters of the fibrin and ECM-fibrin microthreads. An 
asterisk (*) is used to indicate a statistical significance. * p<0.001, ** p<0.0001, n=8 microthreads 
 Figure 12 shows the comparison of the swelling ratio values as percentages of the varying types 
of ECM-fibrin microthreads. Coupled with the data shown in Table 5 above, for every ECM-fibrin 
microthread concentration, the microthreads swell by nearly or more than 200%. This shows that while 
the incorporated ECM decreases both the dry and wet diameters of the microthreads, it does not 
significantly affect the microthread’s ability to swell and increase its’ surface area.  
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Figure 12 Comparison of the average swelling percentage for each ECM-fibrin microthread type. 
4.3.3 Microthread Mechanical Testing Results 
 Uniaxial tensile testing was used to quantify the mechanical properties of the ECM-fibrin 
microthreads and to determine the effect that ECM incorporation has on microthread mechanical 
properties. The first microthread mechanical parameter that was analyzed was the ultimate tensile 
strength, UTS. Table 6 below shows the mean UTS for each of the ECM-fibrin microthread types. Figure 
13 shows a graphical representation all the resultant data points from each microthread tested. The 
results are presented as individual data points in a vertically aligned scatter plot that shows the first, 
second (mean), and thirst quartiles for each data set. 
Table 6 Mean ultimate tensile strengths of the ECM-fibrin microthread types. (n=32, n=33, n=33, n=25) 
 5% ECM 10% ECM 15% ECM FIBRIN 
ULTIMATE TENSILE 
STRENGTH (MPa) 
1.8 ± 1.2 2.1 ± 1.7 2.4 ± 1.7 1.9 ± 1.3 
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Figure 13 Ultimate tensile strength results for the varying ECM-fibrin microthread types. (n=32, n=33, n=33, n=25) 
 The mean UTS for each ECM-fibrin microthread type shown in Table 6 shows an increase in the 
UTS at 10% ECM and 15% ECM incorporation when compared to fibrin. The 5% ECM showed a decrease 
in mean ultimate tensile strength when compared to fibrin. After statistically analyzing these results it 
was found that the differences in mean ultimate tensile strengths were not statistically significant. 
Another microthread mechanical parameter that was analyzed was the microthread strain at 
failure, SAF. Table 7 below outlines the mean SAF for each of the microthread types. The individual data 
points are represented graphically in Figure 14 as a vertically aligned scatter plot that shows the first, 
second (mean) and third quartile of each data set.  
Table 7 Mean strain at failure (mm/mm) for the ECM-fibrin microthread types. (n=29, n=30, n=32, n=24) 
 5% ECM 10% ECM 15% ECM FIBRIN 
STRAIN AT FAILURE 
(mm/mm) 
0.422 ± 0.302 0.471 ± 0.308 0.488 ± 0.283 0.564 ± 0.353 
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Figure 14 Strain at failure (mm/mm) results for the varying ECM-fibrin microthread types. (n=29, n=30, n=32, n=24) 
 When compared to the mean SAF for the fibrin microthread group, the ECM-fibrin microthreads 
all had a mean strain at failure that was less than the fibrin. Within the ECM incorporated microthread 
groups, a slight increase in mean SAF is seen as the ECM incorporation increases. The statistical analysis 
showed however, that the differences between the mean strains at failure were found to not be 
significant.  
The final microthread mechanical parameter that was evaluated was the microthread elastic 
modulus, E. The elastic modulus is a measurement of the stiffness of a material. Table 8 below shows the 
mean modulus for each of the ECM-fibrin microthread types. Figure 15 represents the individual data 
points graphically as a vertically aligned scatter plot that shows the first, second (mean), and third quartile 
for each data set.  
Table 8 Mean elastic modulus (MPa) for each of the ECM-fibrin microthread types. *p<0.05, (n=29, n=33, n=32, n=21)  
 5% ECM 10% ECM 15% ECM FIBRIN 
ELASTIC MODULUS 
(MPa) 
3.1 ± 3.2 5.9 ± 6.5* 4.7 ± 4.1 2.4 ± 2.3 
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Figure 15 Elastic modulus results of the varying types of ECM-fibrin microthread types. (n=29, n=33, n=32, n=21). An asterisk (*) 
is used to indicate a statistical difference between the elastic moduli for the 10% ECM microthreads and the fibrin microthreads. 
*p<0.05 
 The mean modulus of fibrin was 2.36 ± 2.34 MPa. A comparison of this value to the three values 
for the 5% ECM (3.05 ± 3.18 MPa), 10% ECM (5.90 ± 6.51 MPa), and 15% ECM (4.65 ± 4.05 MPa), shows 
that ECM incorporation increases the elastic modulus of the microthreads. The statistical analysis showed 
significance (p<0.05) between the mean modulus of fibrin microthreads and the mean modulus of 10% 
ECM microthreads. The mean moduli of all ECM-fibrin microthread types are represented by the graph 
below in Figure 16.  
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Figure 16 Mean elastic moduli (MPa) for the varying types of ECM-fibrin microthreads. (n=29, n=33, n=32, n=21). An asterisk (*) 
is used to indicate a statistical difference between the elastic modulus for the 10% ECM microthreads and the fibrin microthread 
modulus. *p<0.05 
 The results from this experiment indicate a few key findings relating the effect that ECM 
incorporation has on structural and mechanical properties of fibrin microthreads. First, the ECM can be 
successfully incorporated into the fibrin microthread extrusion process and the proteins present in cardiac 
ECM can be detected within the microthreads using immunohistochemistry. Secondly, the diameters of 
the microthreads significantly decreases with the addition of ECM into the fibrin. This was seen when 
comparing the diameter of the fibrin only microthreads to the diameters of the varying ECM-fibrin 
microthread concentrations. This decrease in diameter was seen in both dehydrated and hydrated 
microthreads. While the diameters did decrease, the swelling ratio of the microthreads was not affected 
by the ECM incorporation. The control fibrin microthreads showed to swell by a two-fold increase. This 
was also seen in the microthreads that had ECM incorporated into the fibrin. Lastly, we can conclude that 
the results from the uniaxial mechanical testing indicate that the incorporation of ECM into fibrin 
microthreads is neither statistically increasing nor decreasing the ultimate tensile strengths or strains at 
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failure of the microthreads. However, the ECM does increase the stiffness or elastic modulus of the 
microthreads, statistically when incorporated at 10% ECM.  
4.4 Aim 1 Discussion 
This aim sought to explore the effects that ECM incorporation has on fibrin microthread structural 
and mechanical properties. The following discussion seeks to support our results and conclusions gained 
from the first series of experiments.  
4.4.1 Microthread Diameters  
Our first experiment in this aim was to determine how ECM incorporation affects microthread 
diameter. We hypothesized, that when the ECM solution is mixed into thrombin and fibrinogen prior to 
microthread extrusion, the resulting microthreads will have a diameter that is less than pure fibrin 
microthreads. In a study by Nayak, et al., a group researched the effects that a material’s viscosity has on 
electrospun fiber diameter. In the study, Nayak et al. fabricated polypropylene (PP) nanofibers and 
adjusted the PP viscosity prior to electrospinning using additives such as sodium oleate (SO), poly(ethylene 
glycol) (PEG), and poly(dimethyl siloxane) (PDMS). It was found that the shear viscosity of PP decreased 
with the addition of PEG and PDMS and increased with the addition of SO. The results of diameter 
measurements showed a decrease in fiber diameter with the solutions of lower viscosity [100].  
The viscosity of fibrinogen solutions depends on the total protein concentration and the 
temperature of the solution. In a study by Jensen et al., the viscosity of a fibrinogen solution that was at 
5.4g/L at 20⁰C was found to be about 1.1mPa.s [101]. Our fibrinogen solution that we use for microthread 
extrusion is 70mg/mL, or an equivalent 70g/L. While we did not measure the viscosity of our fibrinogen, 
we can assume that when we use it, at room temperature, the viscosity will be higher than 1.1mPa.s. The 
digested ECM solution was visibly less viscous following the solubilization. We hypothesized that when 
this less viscous solution was added to the more viscous fibrinogen, the resulting microthreads would be 
finer than those of pure fibrinogen. Due to the previously mentioned research, we can determine that the 
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viscosity of the ECM solution does affect fibrin microthread formation and the resulting microthread 
diameter. Our findings found that the microthread diameters significantly decreased following the 
addition of ECM into the fibrin microthreads. The decrease in diameter was seen when the microthread 
was both in a dehydrated and hydrated state. However, when we calculated the swelling ratio, we saw 
that all the types of fibrin-ECM microthreads increased their size by nearly 200%. This leads us to conclude 
that while the ECM incorporation does decrease the microthread diameter in both dehydrated and 
hydrated states, the ECM does not affect the microthread capability to swell. The swelling of the 
microthreads is an important factor during stem cell seeding. The microthread ability to increase its 
surface area allows for more potential binding are for stem cell adhesion.  
4.4.2 Microthread Mechanics 
The second experiment in this aim sought to determine the mechanical differences between the 
fibrin only microthreads and the ECM-fibrin microthreads. Our findings found that the mean values for 
strain at failure and ultimate tensile strength did not substantially differ between the different 
concentrations of ECM-fibrin microthreads and fibrin only microthreads. Our results for mean elastic 
modulus values found a significantly higher modulus in the microthreads that were 10% ECM when 
compared to fibrin only microthreads. 
Previous studies have created fibrin and collagen matrices in the hopes of creating a scaffold with 
properties that are superior to fibrin only scaffolds and collagen only scaffolds. These studies have looked 
at both the mechanical properties of fibrin-collagen co-gels as well as their cell seeding abilities. In a study 
by Rowe and Stegemann, bovine collagen, bovine thrombin, and bovine fibrinogen were used to create 
fibrin-collagen mixed tubular constructs of varying protein concentration [99]. During formation, the gel 
constructs were seeded with rat aortic smooth muscle cells (RAMSCs) and cultured for a period of 7 days. 
Uniaxial mechanical testing was performed on the constructs at day 7. The constructs were sectioned into 
rings and subjected strain to failure test at 0.3 mm/s. The study found that in the mixed fibrin-collagen 
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constructs (35-55kPa), the material moduli were significantly increased when compared to pure collagen 
(11.2kPa) and pure fibrin (21.9kPa) constructs. The study also found that the ultimate tensile strength 
(UTS) for the pure collagen construct (4.6kPa) was significantly less than that of the pure fibrin construct 
(27.7kPa). However, the pure fibrin construct was nearly equivalent to the fibrin-collagen construct that 
was 50% fibrin and 50% collagen (28.4kPa). All other fibrin-collagen mixture constructs had UTS values of 
around 20kPa [98]. In a later study by the same group, fibrin-collagen constructs created using either 
bovine thrombin or an ancrod snake venom enzyme to polymerize the constructs. Uniaxial mechanical 
testing was performed on the constructs to compare mechanical properties. This study too found that the 
fibrin-collagen constructs polymerized with thrombin showed significantly increased modulus when 
compared to the control pure collagen scaffolds [103]. These studies concluded that the mechanical 
properties of biopolymer networks can be improved by varying the quantity and ratios of the component 
proteins. A structure-function relationship could be determined by a further study of how the protein 
component fibers interact with each other and with a cellular component [102, 103].  
Our results aligned with the trend that these studies found. The material moduli for the fibrin-
ECM microthreads were greater than that of the fibrin only microthread, significantly between the 10% 
ECM-fibrin and fibrin microthreads. Out study also found that the fibrin microthread UTS was not 
significantly different that the UTS values of all fibrin-ECM microthread types.   
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Chapter 5 Aim #2: Human Mesenchymal Stem Cell Seeding on Fibrin-ECM 
Sutures 
5.1 Introduction 
 The purpose of the experiments in this aim is to determine if the ECM-fibrin microthreads 
promote a higher cell attachment density for human mesenchymal stem cells. In order to evaluate the 
effect that the ECM-fibrin microthreads have, sutures made from a bundle of microthreads will be seeded 
with a suspension of human mesenchymal stem cells for 24 hours. Following, the seeded sutures will 
undergo both qualitative analysis consisting of immunohistochemical staining for cell nuclei and the 
cytoskeletal protein f-actin as well as quantitative analysis consisting of a CyQuant cell proliferation assay.  
 We hypothesize that the ECM present in the fibrin-ECM microthreads will aid in the attachment 
of hMSCs to the sutures. Also, with increasing ECM concentration, we will see an increase in the density 
of cell attachment.  
5.2 Methods 
5.2.1 ECM-Fibrin Microthread Bundle Making 
 To increase the mechanical properties of the fibrin microthreads and increase the area for 
potential cellular attachment, Guyette et al. bundled several microthreads together to create a single 
large diameter microthread to form sutures [39]. ECM-fibrin sutures were created following this same 
manner. Briefly, twelve microthreads were lined up close together on a dark surface and secured using a 
small piece of laboratory tape. The microthreads were then hung by the tape using a clamp. The initial 
length of the bundle of threads was measured to ensure the bundle was not overstretched in the final 
step of the bundling process. The threads were grouped together by dragging a drop of DI water along 
the threads until the entirety of the bundle was hydrated. The bundle was then twisted in a clockwise 
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motion from the bottom of the bundle to entwine microthreads together. The unsecured end of the 
bundle was then clamped and pulled tightly so that the final length of the bundle should be close to that 
of the original length of the dry unbundled microthreads. This bundling process can be seen in Figure 17 
below.  
 
Figure 17 Microthread bundling process. Left: 12 individual microthreads are bound together with lab tape. Middle: 
Microthread cluster is hung on a lab stand and hydrated with DI water and then twisted together. Right: The bundle is stretched 
taught to dry. 
5.2.2 ECM-Fibrin Suture Production 
 Microthread bundles were cut to 5 cm lengths and threaded through the eye of a size 26, 3/8 
circle reverse cutting surgical suture needle (Havel’s Inc., Cincinnati, OH). With the needle situated so that 
it is placed in the middle of the bundle, the bundle was hydrated in DPBS for twenty minutes. Following 
hydration, the needle was clamped in curved hemostats. The bundle ends were then folded over the 
needle and adjusted to be the same length on either side of the needle, in case the bundle moved during 
DI 
H O
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handling. The ends were then twisted in a clockwise motion to entwine the bundle, then clamped using a 
second hemostat and pulled taught and left to dry. After the suture was completely dry, it was removed 
from the hemostats and cut to a final length of 2 cm. This process can be demonstrated in Figure 18 below.   
 
Figure 18 A. A 5cm section of a bundle is cut. B. The bundle is threaded through the eye of a needle. The bundle will then be 
hydrated to 20 minutes in DPBS. C. The hydrated bundle is twisted together and stretched between two hemostats. D. A 2 cm 
fibrin suture. 
 For future seeding experiments, the sutures were placed in a specially designed bioreactor. This 
bioreactor consists of a section of gas-permeable Silastic silicone tubing (1.98 mm inner diameter, Dow 
Corning, Midland, MI) cut to approximately 5 cm. A slide clamp is used to secure the suture needle in the 
tube as well as a 27-gauge needle that will be used to deliver a cell suspension to the suture during 
seeding. The bioreactor system as well as a second slide clamp was placed in an instant sealing pouch 
(Chex-All II, Long Island City, NY). Sutures were sterilized via ethylene oxide sterilization for 14 hours and 
were degassed for at least 24 hours before cell seeding. The seeding bioreactor can be seen in Figure 19 
below. A detailed procedure of the bundling and suture making process can be found in Appendix D.  
A 
C 
B 
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Figure 19 Suture housed inside a bioreactor. Gas permeable silicone tubing s used to allow ethylene oxide sterilization to occur 
as well as gas exchange for cell survival during seeding. A 27G needle will be used to deliver DPBS and the cell suspension. The 
slide clamps are used to create a seal and hold the cells within the bioreactor. 
5.2.3 Cell Culture 
 Human mesenchymal stem cells (hMSCs; Lonza, Walkersville, MD) were cultured in Mesenchymal 
Stem Cell Growth Medium (MSCGM; Lonza PT-3001, Walkersville, MD) in compliance with the 
manufacturer’s guidelines. Cells were grown until they reached between passages 5 and 7 before they 
were used for cell seeding experiments.  
5.2.4 Suture Seeding 
 Sterile sutures, prepared according to section 5.2.2, were used in hMSC seeding experiments. For 
each seeding experiment, 8 sutures of each of the four types of microthreads were used. Within the group 
of 8 sutures, 6 sutures would be seeded with hMSCs and 2 sutures would be seeded with media only and 
would act as controls for further analysis. This cell seeding experiment was performed 5 separate times.  
The procedure to seed the sutures with hMSCs followed a protocol previously developed by 
Guyette et al [39]. Briefly, in a biological safety hood, the sutures were first hydrated in sterile DPBS for 
at least twenty minutes. During the hydration, a cell suspension of hMSCs at a concentration of 1x106 
Microthread Suture 
27 G hypodermic 
needle 
Suture Needle 
1.98mm I.D. 
Silicone 
Tubing 
Slide Clamp 
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cells/mL was created. After removing the DPBS, sutures were seeded with 100uL of the hMSC cellular 
suspension, delivering approximately 50,000 cells per 1 cm of suture. This was done by drawing 100uL of 
the cell suspension into a sterile 1mL syringe via a 20-gauge hypodermic needle. The syringe was then 
detached from the 20-gauge needle and re-attached to the 27-gauge needle included in the suture 
bioreactor. The cell suspension was injected into the tubing containing the suture. After removing the 
syringe and 27-gauge needle, the second slide clamp included with the bioreactor was placed onto the 
tube to seal the bioreactor. Bioreactors were placed into a vented 50mL conical tube and placed onto a 
Scilogex MX-T6-S rotator in a 37°C incubator (5% CO2, atmospheric gas concentration). The samples were 
rotated for 24 hours. A more detailed procedure of hMSC cell seeding onto sutured can be found in 
Appendix E.  
5.2.5 Cell Seeding Quantitative Analysis: CyQuant Cell Proliferation Assay 
 The CyQuant cell proliferation assay kit (Molecular Probes, Eugene, OR) uses a DNA stain to 
fluorescently label DNA and standard curve to correlate the fluoresced DNA to a number of cells. Of the 
original 6 sutures from each thread type that were seeded with cells, 4 were used in this CyQuant assay. 
One of the control sutures with media only was also used as the control for this assay.  
Following the suture seeding protocol described in 5.2.4 previously, the sutures were removed 
from the bioreactors and removed from the suture needle. The sutures were then placed in 500µL of DPBS 
in 1.7mL microcentrifuge tubes. Sutures were then centrifuged for 5 minutes at 2000 RPM to remove any 
non-adherent cells. After centrifugation, 400µL of the DPBS was removed from each microcentrifuge 
tubes and the samples were placed in a -80˚C freezer overnight. The DPBS lyses the cells in the freezer 
and releases the DNA in solution. After freezing the samples overnight, the samples were gradually 
brought to room temperature. Once fully thawed, the samples were frozen a second time at -80˚C for at 
least 1 hour to ensure total cell lysis. The samples were then removed from the freezer and brought to 
room temperature a second time.  
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After reaching room temperature, 400µL of a cell lysis buffer was added to each sample 
microcentrifuge tube. The CyQuant cell lysis buffer consists of 1mL of the stock cell lysis buffer included 
in the kit, 50µL of CyQuant GR fluorescent dye and 19mL of DPBS. The microcentrifuge tubes were lightly 
agitated after the addition of the lysis buffer using a Vortex Genie to mix the lysis buffer and microthread 
sample.   
 In order to properly quantify the number of cells seeded onto the sutures, a standard curve of 
cells is used to correlate the amount of DNA detected by the assay to the number of cells. The standard 
curve consists of a starting cell suspension of 120,000 hMSCs in 100µL of DPBS. This cells suspension was 
created according to the following steps. First, a cell suspension of 120,000 cells per 1mL of media is 
created and placed into a 1.5mL microcentrifuge tube. The suspension is then centrifuged at 2000 RPM 
for 5 minutes. The media is then removed from the microcentrifuge tube and 500µL of sterile DPBS is 
added to the cells. The cells are then centrifuged again at 2000 RPM for 5 minutes. Finally, 400µL of DPBS 
is removed from the microcentrifuge tube, leaving a final cell suspension of 120,000 cells in 100µL of 
DPBS. This cell sample is then frozen overnight at -80˚C to lyse the cells in the cell suspension. After 
freezing, the cell suspension was brought to room temperature and 900µL of the cell lysis buffer was 
added to the microcentrifuge tube. This solution was then briefly vortexed.  
Using a flat bottomed 96 well plate, 100uL of the CyQuant lysis buffer was added to wells in 
columns 1-4 and rows B-H. In row A, columns 1-4, 200µL of the DNA cell suspension for the standard 
curve, approximately 24,000 hMSCs, was added. Immediately afterwards, 100µL of the solution in well A1 
was transferred to well B1 and mixed thoroughly with the 100µL of cell lysis buffer present in the well. 
This process was then repeated down the column to cell G1 and then repeated for columns 2, 3 and 4. An 
additional 100µL of cell lysis buffer was added to each well A1-H4 to bring the total volume in each well 
to 200µL. Row H contained no cells to serve as blanks for the standard curve. The standard curve is 
illustrated in Figure 20. 
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Figure 20 Schematic of a 96-well plate used for CyQuant cell proliferation assay. In Columns 1-4 and Rows A-H, a standard curve 
is created to correlate the amount of DNA detected on the sutures to a set number of cells. 
Following the DNA standard curve preparation, the suture samples were each lightly vortexed 
before being removed from their individual microcentrifuge tubes and placed on microscope slides and 
hydrated in DPBS. Next, 100µL of the cell lysis buffer/cell solution for each sample was added into four 
wells of the 96 well plate. Once all samples had been added to the 96 well plate, the plate was placed in 
a Victor3 1420 Plate Reader to record the optical density at 480 nm. The standard curve was created using 
the values from A1-H4 and each sample reading was correlated to number of cells. The fluorescent reading 
for each of the four wells per suture were averaged to calculate the average number of cells per 
centimeter of suture. Figures 21 and 22 illustrate the orientation of the seeded and control samples in the 
96-well plate. Two 96-well plates are used in order to accommodate for the standard curve as well as the 
number of samples seeded during each experiment performed.  
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Figure 21 Complete 96-well plate used for CyQuant. This first plate contains the standard curve as well as seeded and control 
suture samples for each suture type. 
 
Figure 22 The orientation of samples for the second 96-well plate used for CyQuant. 
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Following the CyQuant assay, the now lysed sutures were fixed and stained with Hoescht (1 in 
6000µL of DPBS for 5 minutes). Following, they were viewed under a Leica Upright DMLB2 fluorescent 
microscope to confirm that all cells have been removed during the cell lysis process. A detailed version of 
this procedure can be found in Appendix F.   
5.2.6 Cell Seeding Qualitative Analysis: Hoescht and Phalloidin Fluorescent Staining 
 The remaining 2 seeded sutures and one control suture were used to qualitatively assess the 
hMSC seeding with the use of fluorescent staining. Sutures were removed from their bioreactors following 
24 hours of rotation with the cell suspension. They were then rinsed twice with DPBS for 5 minutes to 
remove any non-adherent cells. Sutures were then fixed in 4% paraformaldehyde in DPBS for 10 minutes. 
Following two more DPBS washes, the cells were permeabilized using 0.25% Triton X-100 (Sigma Aldrich) 
for 10 minutes. Then sutures were rinsed another two times with DPBS and blocked for 30 minutes using 
1% BSA in DPBS. Cytoskeleton filament actin (f-actin) present in microtubules and microfilaments were 
stained with Phalloidin at 2.5% (conjugated to AlexaFluor 488, Invitrogen, Carlsbad, CA) or 50 in 1950uL 
in DPBS for 30 minutes. Sutures were then rinsed two times in DPBS. Cell nuclei were counter-stained 
with Hoechst 33342 dye (Invitrogen, Life Technologies, Eugene, OR) at 0.0167% or 1 in 6000µL in DPBS for 
5 minutes. Sutures were rinsed two final times in DPBS.  
 Sutures and cells were visualized with a Leica Upright DMLB2 fluorescent microscope at 20X 
magnification. Images were also taken on a Leica TCP SP5 confocal laser scanning microscope at 20X 
magnification. Following confocal imaging, coverslip spacers were added and the sutures were sealed with 
CytosealTM 60 and covered with glass coverslips. Images were qualitatively assessed for cell coverage and 
morphology on the suture. A detailed protocol for Hoescht and Phalloidin staining can be found in 
Appendix G. 
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5.3.7 Statistical Analysis 
All results are presented as mean ± standard deviation. The cell seeding data obtained from the 
CyQuant cell proliferation assays were first analyzed to remove data point outliers. The results were then 
compared using an ordinary one-way ANOVA test.  
5.3 Aim 2 Results 
5.3.1 CyQuant Cell Proliferation Assay 
 Sutures created from the varying ECM-fibrin microthread types were seeded with 100,000 human 
mesenchymal stem cells for 24 hours. Following, a quantitative CyQuant cell proliferation assay was 
performed in order to determine the exact number of cells seeded onto each suture. Table 9 below shows 
the average number of cells that successfully attached to each microthread type. Figure 23 below 
represents these values graphically.  
Table 9 Average number of cells seeded on each ECM-fibrin suture type as determined through a CyQuant cell proliferation 
assay. (n=15 sutures) 
 5% ECM 10% ECM 15% ECM FIBRIN 
AVERAGE NUMBER 
OF CELLS SEEDED 
9555±3000 12485±8000 10658±5000 9710±3000 
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Figure 23 Cell Seeding of the varying types of fibrin-ECM microthreads quantified using a CyQuant DNA Assay, n=15 
A one-way ANOVA revealed that the mean number of hMSCs seeded onto the fibrin sutures was 
not statistically different from the mean number of cells seeded onto the ECM-fibrin based sutures.  
5.3.2 Hoescht and Phalloidin Immunohistochemistry 
Along with the quantitative CyQuant cell proliferation assay, seeded sutures also underwent a 
qualitative analysis consisting of immunohistochemical staining for Hoescht 33342 for cell nuclei and Fluor 
488 conjugated Phalloidin for the cytoskeletal protein, f-actin. The stained sutures were viewed and 
imaged under a fluorescent inverted microscope as well as a fluorescent confocal microscope. Figure 24 
below shows the images gained from imaged the seeded sutures under an inverted fluorescent 
microscope. The column on the left consists of the images taken for the Hoescht channel where cell nuclei 
were visible. The middle column consists of the images taken for the Fluor 488 channel, where the 
Phalloidin stain was visible showing us the f-actin that had been laid down by attached cells. The final 
column on the right is an overlay image of the two channels brought together.  
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Figure 24 Fluorescent inverted microscope images of seeded sutures after being stained for hoescht (cell nuclei) and phalloidin 
(f-actin) taken at 10X magnification. Left: Images of the sutures taken using the Hoescht objective Middle: Images of the sutures 
taken using the Fluor 488 (Phalloidin) objective Right: An overlay of the two channels. Scale bar=100um 
 Figure 25 below shows the confocal imaging of the stained seeded sutures at 20X magnification.  
These images were taken along with the inverted fluorescent microscope images above in order to obtain 
higher quality and higher magnification images of different areas on the sutures. Because each suture is 
made from 24 individual microthreads, obtaining in-focus images on either an upright or inverted 
microscope proved to be difficult. A confocal microscope provided us with clear images that showed us a 
clearer view of the cell nuclei and the f-actin cytoskeleton that was created by the cells attached to the 
sutures.  
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Figure 25 Confocal fluorescent microscope images of seeded sutures after being stained for hoescht (cell nuclei) and phalloidin 
(f-actin). 
5.4 Aim 2 Discussion 
 This aim sought to determine the effect that ECM incorporation into fibrin microthreads has on 
the cell seeding capability when the microthreads are used in the form of a suture. The following 
discussion seeks to support our findings and conclusions gained from our 24-hour seeding experiment.   
 A study by Park et al investigated the effects of five hydrogels on the differentiation of human 
adipose stem cells (ASCs). The five hydrogels were collagen, fibrin and hyaluronic acid, collagen and 
hyaluronic acid and fibrin and collagen. The co-gels were created in a 1:1 ratio. During gelation, a 
suspension of 200,000 ASCs was mixed with the hydrogel and cultured for 7 days. The ASCs were 
transfected with lentivirus-expressing green fluorescent protein (GFP) prior to gelation. Following culture, 
the total DNA content was measured using a PicoGreen cell proliferation assay. The cells in the hydrogels 
Fibrin 5% ECM 
10% ECM 15% ECM 
f-actin 
nuclei 
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were also viewed for cell elongation and shape at day 7. This study found that the cells grown in the fibrin 
based hydrogels (fibrin only, fibrin-collagen, and fibrin-HA) had significantly higher levels of DNA when 
compared to the collagen based gels (collagen only and collagen-HA). However, it was found that there 
was no significant difference between the fibrin based hydrogels, whether they were single component 
(fibrin only) or dual component (fibrin-collagen and fibrin-HA). The study also found that cells appeared 
to be more elongated after 7 days of culture in the fibrin-collagen and fibrin-HA hydrogels when compared 
to the fibrin only, collagen only, and collagen-HA hydrogels [104].  This conclusion was also seen in a 
separate study by Rowe and Stegemann [102]. 
 The results from the 24-hours hMSC seeding experiment on the varying fibrin-ECM microthread 
type sutures revealed that there was no statistical difference between the number of cells that 
successfully attached to the fibrin sutures and the fibrin-ECM sutures. This conclusion aligns with the 
aforementioned studies that found no statistical difference in adipose stem cell attachment between 
fibrin only and fibrin-collagen hydrogels.  
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Chapter 6: Aim #3: Evaluate Endothelial Progenitor Outgrowth Cell 
Outgrowth 
6.1 Introduction 
The purpose of this aim is to determine if the ECM-fibrin microthreads promote a greater 
endothelial cell outgrowth. In order to evaluate the effect the ECM-fibrin microthreads will have, we have 
modified a standard scratch assay. In brief, human endothelial progenitor outgrowth cells (hEPOCs) will 
be subjected to a scratch assay by scratching the cells with a 200uL micropipette tip. Within the scratch, 
microthreads, either a 15% ECM-fibrin microthread or a fibrin microthread, will be placed and secured. 
The outgrowth of the cells toward the microthreads will be evaluated at 0, 6, 12, 18, and 24 hours by 
imaging the cell movement and calculating the total distance the cells move.  
We hypothesize that the ECM incorporated into the microthreads will provide signaling cues to 
promote cells to migrate toward the microthread faster than the cells subjected to a fibrin only 
microthread or no microthread.  
6.2 Methods 
6.2.1 Cell Culture  
Prior to cell plating, a sterile 6-well plate was marked with 2 parallel dotted lines down the center 
of each well as illustrated in Figure 26. These two lines will be used as a guide to scratch the wells for 
outgrowth. The dotted lines will also be used as reference points to image the outgrowth assay at the 
same locations over time.  
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Figure 26 Schematic of the 6-well plate used for the outgrowth assay. Each plate was marked with 2 parallel dotted lines prior to 
cell culture. 
Human endothelial progenitor outgrowth cells (hEPOCs; Biochain Z7030001, Newark, CA) were 
cultured in human endothelial progenitor outgrowth cell growth medium (Biochain Z7030003) in 
compliance with the manufacturer’s guidelines. Upon arrival from Biochain, the cells were immediately 
plated into 6-well plates at 10,000 cells/ cm2 at passage 4 in preparation for a scratch assay. Cells were 
grown until they reached full confluency. The cells were used at either passage 4 or 5 as later passages of 
cells failed to continue growing. A detailed protocol to the preparation of the 6-well plates can be found 
in Appendix H.1.  
6.2.2 Microthread Sample Preparation for Outgrowth 
 For this experiment, in one 6-well plate, 2 wells will be subjected to a fibrin microthread within 
the scratch, 2 wells will have a 15% ECM-fibrin microthread within the scratch and 2 wells will serve as 
controls and will have no microthreads within the scratch. Constructs were created in order to secure the 
microthread within the scratch in place to avoid microthread movement. 
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 Each construct consists of a 1.5 cm section of 50 mL polypropylene conical tube. The conical tube 
section was cut from the original conical tube by heating a scalpel over a bunsen burner and cutting 
through the tube. Each conical tube section used for the experiments were then sanded to have even 
edges. The conical tube section was then attached to a stainless-steel washer using medical grade silicone 
adhesive from Bluestar Silicones.  
Microthreads were then adhered to the conical tube and washer constructs. A 3cm section of 
either a fibrin or 15% ECM microthread was cut and laid across the bottom side of the washer, opposite 
side of the conical tube section. The microthread section was then oriented so that it lay across the 
approximate middle of the washer. Using the silicone adhesive, the microthread was secured to the 
construct and left overnight to allow the adhesive to cure. The control wells for this experiment would 
have a blank construct place within the well. These constructs consisted of only the conical tube section 
and washer. A schematic of the washer and conical tube construct is seen below in Figure 27. A detailed 
procedure for the production of the microthread constructs can be found in Appendix H.2. 
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Figure 27 Microthread construct consisting a stainless-steel washer and a section of a polypropylene 50 mL conical tube These 
two components are brought together using silicone adhesive. Finally, the microthread is placed in the middle of the construct. 
6.2.3 Endothelial Progenitor Outgrowth Cell Outgrowth 
Once the hEPOCs had reached full confluency in each well of the 6-well plate, the outgrowth assay 
could begin. First, the hEPOC growth media was removed from each well. Then, using a 200uL 
micropipette tip, a scratch was drawn down the middle of each well between the dotted lines. Following 
the scratch, each well was gently washed with 2000uL of sterile DPBS two times to remove cells that were 
detached due to the scratch.  
 Following, the microthread constructs were placed in their designated wells so that the 
microthread would lie within the scratch. With the constructs placed within the well, 2000uL of hEPOC 
growth medium was added to each well. Plates were viewed under a Nikon Inverted Light Microscope to 
confirm the microthread was within its respective scratch. Adjustments of the construct were made until 
each microthread was within each scratch.  Figure 28 below is a schematic of the final setup of the 
constructs within the 6-well plate.  
PP Conical Tube Section 
Silicone Adhesive 
Microthread 
SS Washer, I.D.:2cm 
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Figure 28 Schematic of a 6-well plate that has been prepared for the EPOC Outgrowth assay. The scratch has been made and the 
microthread constructs have been placed within the scratch. 
 Once the constructs were in place, the wells were imaged on a Leica DMIL LED inverted 
microscope at 20X for the 0-hour time point. Each well was imaged at the specific points were the dotted 
lines were visible within the washer. Depending on how many sets of dots fell within the boundary of the 
construct, this was between 4 and 5 locations for imaging. Imaging was repeated for all locations at 6, 12, 
18, and 24 hours. A detailed procedure of the 24-hour EPOC outgrowth assay can be found in Appendix 
H.3. 
6.2.4 DAPI Staining 
 Following the final outgrowth images being taken at 24 hours, the microthreads present within 
the wells of the 6-well plates were removed from the wells and subjected to a DAPI stain to evaluate any 
cell attachment onto the microthreads from the outgrowth. Briefly, the microthread constructs were 
removed from their respective wells. The microthread was cut from the construct and placed onto a 
microscope slide. Each microthread was rinsed in DPBS twice for 5 minutes each. Next the microthreads 
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were fixed in 4% paraformaldehyde in PBS for 10 minutes and then washed in DPBS for 5 minutes three 
times. Any cells on the microthreads were then permeabilized with a 0.25% Triton-X 100 for 10 minutes. 
Following three more washes in DPBS, microthreads were then stained with DAPI (Invitrogen, Life 
Technologies Corporation, Eugene, OR) for 5 minutes. DAPI was obtained from the manufacturer and 
immediately put into solution at 10mg in 2mL of deionized water and kept at -30˚C. For staining, the DAPI 
stock solution was diluted to a concentration of 1ug in 1mL of PBS, or 0.2uL of stock solution in 1000uL 
DPBS. Following the DAPI stain, microthreads were washed in DPBS. This protocol can be found in more 
detail in Appendix I. The microthreads were then analyzed on a Leica SM LB2 inverted microscope. Using 
a handheld tally counter, cells that had migrated onto and attached to the microthreads were counted 
across each microthread.  
6.2.5 Cell Outgrowth Evaluation 
The images taken for each well at each time point were used to measure the percent change in 
the distance between the two sides of the endothelial cell scratch. Using the software ImageJ, each image 
taken for each time point was scaled so that the measurements would be accurate. Once scaled, the 
scratch distance on each image was measured at 10 locations within the scratch. This is done by using the 
line function in ImageJ to draw a horizontal line across the scratch and then using the measuring feature 
to determine the length of the drawn line. Figure 29 below demonstrates the 10 horizontal lines that are 
drawn in parallel down the scratch. Figure 30 shows an image that has been uploaded into ImageJ and 
has had the ten measurements made between the scratch. These 10 measured lengths were then 
imported into Microsoft Excel in order to perform necessary measurements.  
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Figure 29 Ten horizontal lines are drawn in parallel across the scratch and then measured using the measuring function in 
ImageJ. 
 
Figure 30 Ten measurements are made for a single image in ImageJ to calculate the average distance between the scratch for 
this image. 
 A number of calculations were performed to determine the overall percent change in distance 
between 0 and 24 hours for each outgrowth condition. Prior to calculations, every measurement made 
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for each well at each time point was imported into excel. As mentioned previously, ten measurements 
were taken for each location in each well. These measurements were taken in the same area each time. 
The first calculation made was to subtract the final distance from the initial distance for each 
measurement at each location in each well. This calculation provides us with a data set of the differences 
in the distances between the scratch. Next these measurements were used to determine the percent 
change in distance by dividing the change in distance over the initial distance and multiplying by 100.  
 Other calculations were made in order to determine the distance travelled between each time 
point as well as an average change in distance for each well. These calculations were not used in the final 
analysis of the outgrowth assay, however, they can be found in Appendix J. In order to compare the three 
well conditions, fibrin microthread, 15% ECM microthread and blank, the overall average percent change 
in distances were compared.  
6.2.6 Microthread Media Control  
 A control is required to compare the DAPI staining to, so we chose to run a control media-only 
experiment. This experiment consisted of incubating a fibrin microthread and a 15% ECM microthread in 
media for 24 hours. The experiment was set up in the same manor of the initial outgrowth assay. 
Microthreads were cut into sections measuring approximately 3cm and attached to the constructs 
described previously. Once sterilized, the microthread constructs were placed in a 6-well plate and 
incubated in 2mL of complete EPOC growth media for 24 hours. The 6-well plate consisted on 3 fibrin 
constructs and 3 15% ECM constructs. Following the 24-hour incubation, each construct was removed 
from the 6-well plate and the microthreads were cut from the contract and placed on a glass slide. The 
microthreads then underwent the DAPI stain protocol mentioned previously. Following the stain, the 
microthreads were viewed and imaged on a Leica Upright DMLB2 fluorescent microscope at 10X 
magnification. The images taken were then compared to the microthreads that were used in the EPOC 
outgrowth.  
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6.2.7 Statistical Analysis 
All results are presented as mean ± standard deviation. The individual initial and final distance 
measurements were used to determine the change in distance between the scratch for each 
measurement. The individual changes in distance were then analyzed to remove outliers from the dataset. 
Also analyzed were the comparisons of all the initial and final distances separately in order to show that 
the initial distances for each migration condition did not significantly vary. The results were then 
compared using an ordinary one-way ANOVA test. Statistical significance was determined as p< 0.0001. 
The number of cells counted on the microthreads following the outgowth assay were also analyzed using 
a t-test.  
6.3 Aim 3 Results 
6.3.1 Endothelial Progenitor Outgrowth Cell Migration 
A modified scratch assay was used to determine the effect that the ECM in the ECM-fibrin 
microthreads has on endothelial cell outgrowth. As described previously, endothelial progenitor 
outgrowth cells (EPOCs) were cultured in a 6-well plate and then subjected to a 24-hour scratch assay. 
When the scratch in the culture was created, either a fibrin microthread or a 15% ECM microthread was 
placed within the scratch. Wells with no microthread within the scratch were used as controls. The 
outgrowth of the EPOCS was evaluated over 24 hours by imaging each well at specified locations every six 
hours. From these images, measurements of the distances between the scratch were taken using ImageJ 
software. Figure 31 below shows a time progression of the EPOC outgrowth under each condition: 15% 
ECM microthread, fibrin microthread, and control. From these images, we can see that wells containing a 
15% ECM microthread fully closes at the 24-hour time point while the wells containing the fibrin 
microthread or no microthread do not full close. This initial result suggests that the ECM incorporated into 
the 15% ECM microthread does play a role in rate of the EPOC outgrowth.  
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Figure 31 EPOC outgrowth progression over 24 hours under the conditions of a control (no microthreads), a fibrin microthread 
and a 15% ECM microthread. 
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6.3.2 Evaluation of Endothelial Progenitor Outgrowth Cell Outgrowth  
In order to quantify the effect that ECM has on EPOC outgrowth, the images taken for each well 
at each time point were used. For each well in the 6-well plate, four or five images were taken at specific 
locations for each time point. Each of these images were used to measure the distances between the sides 
of the scratch at the specific location every 6 hours. These measurements were then used in a series of 
calculations to determine the overall percent change in the distance between the sides of the scratch for 
each condition. Figure 32 below shows the distance between the scratch over time for each of the three 
conditions.  By fitting a linear line to the trends, we were able to determine the slopes of the lines. As it 
can be seen on the graph, the 15% ECM microthread condition for outgrowth had a steeper slope (m=-
287) than the slopes for the fibrin microthread (m=-237.25) and control (m=-221.49) conditions.  
 
Figure 32 Outgrowth of EPOCs over time. 
Figure 33 below shows the final values for the average percent change in distance for the 
EPOC scratch for wells with a 15% ECM microthread, a fibrin microthread or no microthread. On 
average, the wells that contained a 15% ECM microthread within the scratch closed 77 ± 21% of 
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their initial distance. Respectively, the average percent distance closed for wells containing a fibrin 
microthread within the scratch and the control wells were 61 ± 33% and 59 ± 34%. A one-way 
ANOVA determined that the percent change in distance at 24 hours was significantly higher in the 
15% ECM microthread wells when compared to the fibrin microthread and control wells.  
 
Figure 33 Mean percent change in distance between the edges of the scratch for each outgrowth condition. An asterisk (*) is 
used to indicate a statistical difference between outgrowth conditions. *p<0.0001. n=6 
 In order to demonstrate that each well in the 6-well plate was starting at the same distance, 
the measurements of the average initial distances for each condition are presented below in Figure 
34. As it is shown in the graph, the distance between the scratch for each condition at 24 hours if 
nearly the same. For 15% ECM microthread wells, the average initial distance was 1528 ± 248 
um. For fibrin microthread wells, the average initial distance was 1590 ± 44 um. For control wells, 
the average initial distance was 1542 ± 379 um.  
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Figure 34 A comparison of the initial and final distances for each outgrowth condition. An asterisk (*) is used to indicate 
significance between the final distances between the scratch. *p<0.0001 
6.3.3 Endothelial Progenitor Outgrowth Cell DAPI Stain 
Following the 24-hours EPOC outgrowth, the microthreads that were present within the scratch 
for 24 hours were removed from their respective wells and stained for DAPI (cell nuclei) to evaluate 
potential EPOC outgrowth onto the microthreads. The control group for this staining experiment 
consisted of 15% ECM and fibrin microthreads that were incubated in EPOC growth medium for 2 hours. 
This control was used in order to rule out any autofluorescence. In Figure 35 below, 15% ECM 
microthreads have been stained for DAPI following a 24-hour EPOC outgrowth and 24-hour EPOC growth 
medium incubation. The 15% ECM microthread that underwent the EPOC outgrowth assay shows an 
abundance of cell nuclei that have been stained with DAPI, indicating EPOCs have migrated and attached 
to the microthread. The control 15% ECM microthread does not show any indications of false cell staining. 
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Figure 35 15% ECM microthreads stained for DAPI (cell nuclei) following Left: a 24-hour EPOC outgrowth assay Right: a 24-hour 
EPOC media control incubation 
 Similarly, Figure 36 below shows fibrin microthreads that have been stained following the 24-
hours EPOC outgrowth assay as well as the control EPOC growth medium incubation. The fibrin 
microthread that underwent the 24-hour EPOC outgrowth assay shows some stained cell nuclei indicating 
that EPOCs did attach to the fibrin microthread. The control fibrin microthread does not show any false 
cell staining.  
 
Figure 36 Fibrin microthread stained for DAPI (cell nuclei) following Left: a 24-hour EPOC outgrowth assay Right: a 24-hour EPOC 
media control incubation 
 When comparing the images taken for the 15% ECM microthread and the fibrin microthread that 
underwent the EPOC outgrowth, the 15% ECM microthread shows a much higher number of stained cell 
nuclei of cells that have attached to the microthread. The fibrin microthread does show some cell nuclei 
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that have attached to the microthread suggesting that fibrin does play a minor role in endothelial 
progenitor cell outgrowth.  
 In order to quantify the results of the EPOC outgrowth onto the microthreads, the DAPI stained 
cell nuclei were counted by hand using a tally counter. Figure 37 below shows the average number of DAPI 
stained cells counted on the microthreads. For each condition, 15% ECM and fibrin, there were a total of 
six microthreads from all the outgrowth assays that were stained for DAPI and evaluated. Out of the six 
15% ECM microthreads, stained EPOCs were seen on three. As seen in the graph, on average there were 
114 ± 162 cells on the 15% ECM microthreads. For the fibrin microthreads, cells were only seen on one of 
the six microthreads that underwent the outgrowth assay. The average of the cells counted on fibrin 
microthreads was 6.67 ± 16.2 cells. A t-test revealed that there was no statistical significance between the 
mean numbers of cells that adhered onto the microthreads.  
 
Figure 37 Mean number of EPOCs counted on microthreads following a 24-hour outgrowth assay. 
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6.4 Aim 3 Discussion 
This experiment sought to explore the angiogenic potential that the ECM-fibrin microthreads may 
have through an endothelial progenitor cell outgrowth assay. The extracellular matrix plays a key role in 
regulating angiogenesis. In the event of injury or ischemia, the matrix is modulated to recruit endothelial 
progenitor cells to injury site. This causes the number of circulating endothelial progenitor cells to increase 
and promote blood vessel formation and tissue regeneration [105].  
Many extracellular matrix molecules, including collagens, laminins, and fibronectins, play specific key 
roles in endothelial cell survival, growth, migration, and tube formation. Collagen I specifically promotes 
endothelial cell tube formation [103]. Other collagens are known to promote cell adhesion and migration 
(Collagen IV) as well as stabilizes endothelial cell tubes (Collagen XVIII) [106]. Collagen matrices have been 
shown to support endothelial progenitor cell differentiation into endothelial cells [107]. According to a 
study by Crister et al., endothelial progenitor cells vascularize collagen-based matrices in vivo [108]. 
Collagen has also been shown to protect endothelial progenitor cells against apoptosis [107]. 
Laminins are a group of proteins that are also known to encourage angiogenic events. Specific 
laminins play key roles such as laminin 1 specifically promoting endothelial cell tube formation and laminin 
8 promoting endothelial cell morphogenesis [106, 107]. Finally, fibronectin too encourages endothelial 
cell adhesion, growth migration and survival [106, 107]. These findings thus show that the extracellular 
matrix and its proteins have pro-angiogenic properties.  
Fibrin has also been shown to be involved in the regulation of endothelial progenitor cell biology. In a 
study by Barsotti et al., endothelial progenitor cells in a fibrin matrix showed the ability to differentiate 
into endothelial cells and migrate and integrate into newly formed blood vessels in vivo [109].  
A study by Singelyn et al. developed an injectable cardiac extracellular matrix based hydrogel to 
promote angiogenesis in vivo. In the study, they performed an in vitro migration assay of vascular cells. 
Using a Chemotaxis 96-well Cell Migration Assay Kit, the group evaluated the migration of human coronary 
84 
 
artery endothelial cells (HCAECs) and rat aortic smooth muscle cells (RASMCs) toward a cardiac ECM, 
collagen, fetal bovine serum, and pepsin. The results of the migration assay revealed that the cardiac ECM 
increased the migration of the RASMCs significantly (p<0.001). The results also showed that while it was 
not significant, the HCAECs followed the same trend of increased migration toward the cardiac ECM 
matrix. The study concluded that the cardiac ECM hydrogel promoted migration of both cell types in vitro. 
The study further evaluated the injectable hydrogel in vivo. The hydrogel was injected into the hearts of 
rats. The hearts were analyzed at a short term 4-hour time point as well as a long term 11-day time point. 
Following immunohistochemical staining, the study revealed that after 11 days, endothelial and smooth 
muscle cells had significant infiltration into the matrix region [97].  
The in vitro results of this study coincided with the outgrowth assay results we obtained from our 
experiment. Our study showed a significant increase in endothelial progenitor cell outgrowth toward the 
15% ECM-fibrin microthreads. Our results also showed that endothelial progenitor cells migrate toward 
the microthreads and adhere to the surface of the microthreads. From the known roles that extracellular 
matrix molecules play in angiogenesis as well as the role that fibrin plays in endothelial progenitor cell 
outgrowth, our ECM-fibrin microthreads exhibit a high level of angiogenic potential.  
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Chapter 7: Future Work and Recommendations 
The use of fibrin microthreads in the form of a bundled suture has been shown as a novel method for 
the delivery of hMSCs into the infarcted region of a heart used by the Gaudette lab. Fibrin based sutures 
have improved cell engraftment and localization when compared to the tradition intramyocardial (IM) cell 
injections [39]. The Gaudette lab has also shown new methods for improving the sutures potential as a 
stem cell delivery mechanism by prolonging the degradation of fibrin sutures in order to increase cell 
seeding time and ultimately increasing the number of cells that adhere to the sutures for delivery [54].  
We demonstrated that native cardiac extracellular matrix can be incorporated into the fibrin microthreads 
and then used as a bundled suture. These ECM-fibrin sutures have showed the ability to increase 
endothelial progenitor cell outgrowth and attachment to the microthreads when compared to cell 
outgrowth toward fibrin only microthreads and no microthread. The ECM-fibrin microthreads also 
showed increased elastic modulus. These results implicate the potential for the ECM-fibrin microthreads 
to be used as a stem cell delivery mechanism. 
While this study was able to draw conclusions about the use of native cardiac ECM to improve the 
properties of fibrin based sutures, additional research and future studies could provide more 
understanding of the effects that ECM incorporation has on the properties of fibrin microthreads. This 
experiment investigated the effects of ECM incorporation at 5%, 10% and 15% v/v. Performing these same 
experiments on microthreads that are 1% ECM could provide information on how the ECM can affect the 
fibrin microthread properties at the smallest incorporation. These experiments could also give an 
understanding of how important a higher ECM incorporation percentage is.  
Similarly, our study performed the endothelial progenitor outgrowth cell outgrowth using on fibrin 
microthreads and 15% ECM microthreads. We used our highest concentration of ECM in order to 
determine if the EPOC outgrwoth was affected in any way by the ECM. Because we now know that the 
outgrowth of the EPOCs is increased by the ECM incorporation, performing a replicate study using the 5% 
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ECM and 10% ECM microthreads would provide an understanding on how the lower ECM concentrated 
microthreads can affect the EPOC outgrowth. Also, our study found that there was no significant 
difference in the number of endothelial progenitor cells that adhered to the microthreads. In a sample 
size of six, three 15% ECM microthreads had cells while three had zero cells. This resulted in high standard 
deviations. Similarly, with the fibrin microthreads, one out of the six had visible cells that adhered onto 
the microthreads. When comparing the results from the cell counts, the means were found to not be 
statistically different. A higher sample size of microthreads could provide for more data in order to make 
significant conclusions.  
Fibrin degrades by fibrinolysis which is increased during hMSC seeding due to the cells releasing 
fibrinolytic enzymes. Aprotinin, a protease inhibitor, has been shown to decrease the degradation of fibrin 
in cell culture environments [54]. When the ECM is incorporated into the fibrin microthreads, the total 
fibrin concentration is reduced. This reduction in fibrin content could potentially affect the degradation 
of the microthreads. An investigation into the degradation of ECM-fibrin microthreads could determine 
the stability of the microthreads and all us to understand is the ECM incorporation increases or decreased 
the degradation of the microthreads.   
While our hMSC seeding experiments determined that there was no statistical significance in the 
number of cells seeded to the ECM-fibrin based sutures and the fibrin only sutures, further 
experimentation may provide an understanding of the effect that ECM has on the molecular level. 
Performing experiments that determine the cell and matrix interactions would provide an inclination of 
the adhesion of strength of the cells to the microthreads. It is possible that the ECM could create a 
stronger bond between the cells and the microthread. Additionally, the staining of our seeded sutures 
appeared to show a trend of increasing f-actin with increasing ECM concentration. Further 
experimentation could provide an understanding on how the ECM is affecting the cells on a molecular 
level.  
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Therapies using hMSCs have shown that the cells aid in the healing process by reducing the 
inflammation caused by a myocardial infarction. The ultimate goal of using stem cell therapies is to 
regenerate tissue function. For the heart, this means regenerating and restoring total heart function and 
contraction. Induced pluripotent stem cell derived cardiomyocytes are cells that have had genes altered 
in order to become contractile cardiac cells. Efforts have been made to seed these contractile cells on 
fibrin sutures and implant them into healthy rat hearts to evaluate cell delivery and viability. Cardiac 
derived ECM is known to guide cardiac cell migration, proliferation and differentiation. It is possible that 
the cardiac ECM could aid in cardiac cell attachment and viability.  
Finally, while our study was purely in vitro, seeded fibrin sutures have been delivered into healthy and 
infarcted hearts using a rat model. Many studies have been performed on the fibrin only sutures. Because 
the ECM-fibrin based sutures have behaved differently in the in vitro studies, in vivo studies must be 
performed in order to fully determine how the ECM-fibrin sutures compare to fibrin only sutures. Our in 
vitro endothelial progenitor cell outgrowth assay concluded that the ECM-fibrin microthreads are pro-
angiogenic. This conclusion could be confirmed with in vivo studies.  
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Chapter 8: Conclusion 
 The goal of the project was to successfully incorporate cardiac extracellular matrix into fibrin 
microthreads and to explore the effects that the ECM incorporation has on structural and mechanical 
properties as well as hMSC adhesion and EPOC outgrwoth. The ECM incorporation caused an increase in 
the elastic modulus of the microthreads when comparing the ECM-fibrin microthreads to the fibrin only 
microthreads. This increase was especially significant in the 10% ECM microthread group. When 
evaluating the different types of microthread when used as a bundled suture in hMSC cell seeding. The 
sutures that were ECM-fibrin based did not exhibit any significant differences in the cell attachment when 
compared to the fibrin only based sutures. Lastly, when used in a 24-hour EPOC outgrwoth assay, the 
ECM-fibrin microthreads increased the rate of cell outgrowth as well as increased the number of cells that 
adhered to the microthreads when compared to fibrin only microthreads as well as a control with no 
microthread. EPOC outgrwoth toward a 15% ECM-fibrin microthread showed a 16% increase in distance 
travelled by the cells in 24 hours when compared to the outgrowth of cells toward the fibrin only 
microthread and an 18% increase when compared to a blank control. The incorporation of native cardiac 
ECM into fibrin microthreads increases the microthread elastic modulus and is able to increase EPOC 
outgrowth distance and attachment to the microthread.  
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Appendix A: Cardiac ECM Preparation 
A.1. Decellularization of Cardiac Tissue 
Materials: 
 50 mL conical tube 
 Large petri dish 
 Iris scissors 
 Fine tooth forceps 
 1% Sodium Dodecyl Sulfate 
 1% Triton-X 100 
 Dulbeccos Phosphate Buffered Saline 
 Scilogex Tube Rotator 
 Hearts obtained from rats 
Procedure: 
1. Obtain hearts from rats after following animal euthanization and heart extraction. Store hearts 
in DPBS at -30°C 
2. In a large petri dish, place about 10 mL of PBS in the dish 
3. Place heart in the dish and using the fine tooth forceps and the iris scissors, cut up the heart into 
small pieces 
a. Approximately 3mmx3mmx3mm 
4. Once the heart is fully minced, place all heart pieces into a 50 mL conical tube 
5. Add about 25 mL of 1% SDS into the conical tube 
6. Place the conical tube on the tube rotator and rotate overnight 
7. Replace the SDS every 12 hours until the heart tissue pieces are fully transparent 
8. Once the hearts are fully transparent, replace the 1% SDS solution with approximately 25 mL of 
1% Triton-X 100 solution 
9. Replace the Triton-X solution every 12 hours for 24 hours 
10. Following 24 hours of Triton-X immersion, replace the solution with deionized water 
11. Replace the DI water every 12 hours for 24 hours 
12. Once decellularization is complete, place the tissue sections in about 10 mL of DI water for 
storage at -30°C 
A.2. Lyophilization of Decellularized Cardiac ECM 
Materials: 
 Decellularized cardiac ECM (frozen in 10 mL of DI water) 
 Kim wipe 
 Lab Tape 
 Lyophilizer 
Procedure: 
1. Remove the decellularized ECM from the -30°C freezer 
2. Remove the cap of the conical tube and tape a KimWipe over the opening of the tube 
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3. Keep the tube on ice until placed into the lyophilizer 
4. Ensure that the lyophilizer is turned on and has reached the proper conditions 
a. Temperature = -104.3 °C 
b. Pressure = 14 millitorr 
5. Place the conical tube into lyophilizer jars and attach the jar to the machine 
a. To do this place a vacuum seal over the jar and attach the jar to an open site 
b. Turn the white knob 180 degrees so that it is oriented in the up-down direction 
6. Allow the process to lyophilize the tissue until the ECM is visibly dry and all ice crystal are gone 
a. This can take between 24 and 48 hours 
7. Once process is complete, turn the white knob again 180 degrees to release the pressure inside 
the jar 
8. Remove the jar from attachment site and remove sample 
9. Replace the cap on the conical tube and store in a dry area 
A.3. Solubilization of Cardiac ECM 
Materials: 
 Lyophilized cardiac ECM 
 0.1 M Hydrochloric Acid 
 Pepsin from Gastric Mucosa 
 1 M Sodium Hydroxide 
 Weigh boat 
 Disposable Scintillation Vial 
 Scale 
 Stir Plate 
 Stir bar 
 Ceramic Mortar and Pestle 
Procedure: 
1. Obtain lyophilized cardiac ECM 
2. Grind ECM using the mortar and pestle until it is a fine powder 
a. Larger ECM pieces may need to be additionally cut using iris scissors to be successfully 
ground 
3. Once ECM is ground, weight out 100 mg  
a. This is easiest if it is weighed inside the vial in order to ensure no ECM is lost 
4. Weigh 10 mg of pepsin from gastric mucosa and add it to the vial 
a. This is easiest if it is weighed inside a 1.7 mL microcentrifuge tube. Then using 1000 uL 
of 0.1M HCl, mix the pepsin into the HCl and add it to ECM. 
5. Add 0.1 M HCl to the vial. There should be a total of 10 mL of HCL in the vial. 
6. Place a small stir bar in the vial and stir the solution 
7. Stir the solution until all ECM is visibly solubilized. This can take between 3 and 7 days 
depending on the size of the ECM particles within the solution. 
8. Once the ECM is fully solubilized, neutralize the solution with 1M NaOH to a pH of 7.4 
9. Store the solution in the refrigerator for up to 1 week.  
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Appendix B: ECM-Fibrin Microthread Production 
Materials:  
 Extrusion baking pan 
 Syringe pump 
 1 aliquot fibrinogen - 70mg/ml  
 1 aliquot thrombin – 8U/200µl 
 10mM HEPES solution 
 2 - 1mL syringes 
 1 – 3ml syringe 
 1000mL graduated cylinder 
 Clear cup of room temperature water 
 40mM CaCl2 
 1000µl Micropipetter  
 2 sets of fine toothed forceps  
 Cardboard drying box 
 Kimwipes 
 Extruding tube 
 Blending connector 
 Polyethylene Tubing 
 Solubilized ECM solution (10mg/mL) 
Procedure: 
Preparation: 
1. Rinse graduated cylinder with DI water 
2. Fill Graduated cylinder with 500mL of 10mM HEPES solution. Transfer HEPES into silver baking 
pan 
3. Obtain 1 aliquot of Fibrinogen and 1 aliquot of Thrombin from -30C freezer 
4. Obtain 40mM CaCl2 from fridge. 
5. Defrost frozen aliquots by placing them into room temperature water 
6. Once completely defrosted, add 850µL of 40mM CaCl2 into the thrombin, mix thoroughly 
7. Label two 1ml syringes, one as T and one as F 
ECM Preparation: 
1. Obtain the ECM solubilized solution from the refrigerator 
2. The ECM solution must be filtered prior to solution mixing to remove any large sized particles 
that may clog the polyethylene tubing and 27-gauge needle used in extrusion (ID:0.38 mm, 
OD:1.09mm) 
3. Transfer 1000 uL of the ECM solution to a 1.7 mL microcentrifuge tube 
4. Using a 20-gauge needle attached to a 1mL syringe, draw up the whole solution into the syringe 
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5. Transfer the filtered solution to a new 1.7 mL microcentrifuge tube 
6. Repeat step 4 using a 22 gauge-needle 
7. Transfer the filtered solution to a new 1.7 mL microcentrifuge tube 
8. Repeat step 4 again using a 27-gauge needle 
9. Transfer the filtered solution to a new 1.7 mL microcentrifuge tube 
Solution Preparation: 
1. For a 5% ECM microthread solution: 
a. Transfer 950ul of Thrombin and Fibrinogen into new 1.7 mL microcentrifuge tubes 
b. Add 50ul of filtered ECM solution into microcentrifuge tube (Total V=1000 ul) and mix 
thoroughly 
Percentage Volume of 
Thrombin 
Volume of 
Fibrinogen 
Volume of ECM in 
T and F 
5% 950 ul 950 ul 50 ul 
10% 900 ul 900 ul 100 ul 
15% 850 ul 850 ul 150 ul 
20% 800 ul 800 ul 200 ul 
 
2. Using 20 G syringe appropriate withdraw thrombin and fibrinogen into separate labeled syringes  
3. Remove all air bubbles from syringe 
4. Balance the two syringes so that they contain the same volume of solution 
Setting up Machine: 
1. Plug in syringe pump and turn the power on (Power switch is in the back of the machine) 
2. Make sure DIAMETER is set to 4.699mm and the RATE is set to 0.23 mL/min. 
3. Plug the Fibrinogen and Thrombin syringes into the blending connector. The Fibrinogen syringe 
should ALWAYS be placed into the side with the small circle 
 
4. Place syringes into syringe pump. 
 Lift black knob and slide the ends of the syringes under black bar, splitting the two 
syringes with the knob. Make sure syringe body flanges are inserted in to clamp. Release 
black knob. 
 Tighten syringe clamp using the silver nuts. 
5. Make syringe pump block flush with the syringe connector 
T 
F 
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 Push down black button and pinch white piece   
6. Attach polyethylene tubing to the free side of the blending connector 
Thread Extrusion: 
1. Press start on the machine. 
2. Wait for ALL the air bubbles to pass through the PE tubing. Use a Kimwipe to collect anything 
that comes out while air bubbles are passing through. 
3. Once there is a constant flow, start making the threads.  
Hold extruding tube ≈ 4 inches from the end. Drag end of tube horizontally along the bottom of 
the silver pan filled with 10mM HEPES. Move the tube from the left side of the pan to right side 
at a constant rate. At the end of one thread move quickly bring the end of the tube back to the 
left side of the pan, move ≈ 1 inch down and begin a new thread. Repeat until you cannot make 
anymore. *Make sure the end of the tube is clean and free of fibrin debris, wipe clean if needed  
4. Turn off machine once you are done. 
Clean Up Part 1: 
1. Immediately clean tube. Fill a 3ml syringes with water and flush extruding tube with water. 
Remove syringe from extruding tube, withdraw syringe with just air and blow air through 
extruding tube with syringe. Repeat with white co-extruder. 
2. Throw away any used materials into the proper trash receptacle. 
Transferring Threads: 
1. Use the two sets of forceps to take the threads out of the pan.  
 Grab each end of the thread with the forceps 
 Move right hand counterclockwise and left hand clockwise so you can pick up the 
thread.  
 Make sure not to pull too fast and to keep threads in the HEPES as long as possible. 
2. Transfer the threads to the cardboard box. Secure one side to the box and stretch the thread. 
Secure the middle of the stretched out thread to the box. Cut the thread in half then stretch the 
remaining half over the box. One extruded thread should produce two threads 
3. Repeat this for all threads. Leave threads out to dry overnight. 
Clean Up Part 2: 
1. Pour HEPES down the drain and rinse off pan. Dry the pan with paper towel. 
2. Put all items away. 
3. Dispose of any other used items in the appropriate receptacle.  
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Appendix C: ECM Protein Staining Protocols 
Materials: 
 Phosphate Buffered Saline 
 4% Paraformaldehyde (Only needed for tissues/cells that have not been fixed); 
 0.25% Triton-X 
o 0.25% V/V  Triton-X in PBS 
o 10 μL Triton-X in 3990 μL PBS 
 1% BSA 
o 1% V (W)/V BSA in PBS 
o 40 μL in 3960 μL  
 Primary for protein of choice- 1:200 in blocking agent, 1% BSA 
o Fibronectin (anti-fibronectin antibody ab2413) 
 Secondary antibody – goat anti rabbit IgG AF 546 1:500 in BSA 
 Glass slides with microthread sections  
 Hydrophobic marker 
 Slide staining box 
Procedure: 
1. Rinse in PBS 2x 
2. Fix in 4% para for 10 min 
3. Wash PBS 3x, 5 min each 
4. 0.25% Triton-X 100, 10 min 
5. Wash PBS 3x, 5 min each 
6. Block with 1% BSA, 45 min 
7. Leave BSA on negative, aspirate off positive 
8. Primary: 1:200 anti-fibronectin in 1% BSA at 4°C overnight 
9. Wash PBS 3x, 5 min each 
10. Secondary: 1:500 goat anti-rabbit AF 488, 1 hour @ room temp in the dark 
11. Wash PBS 3x, 5 min each 
12. Coverslip, image, store @ -20°C  
The table below shows the concentrations that should be use for the staining of Collagen I and Laminin 
111.  
Protein Primary 
Antibody 
Primary 
Concentration 
Secondary 
Antibody 
Secondary 
Concentration 
Stain 
Color 
Collagen I Anti-Collagen I 1:200µL in 
BSA 
Rabbit Anti-goat 
488 
1:400µL in BSA Green 
Fibronectin Anti-Fibronectin 
ab2413 
1:200µL in 
BSA 
Goat-Anti-Rabbit 
546 
1:500µL in BSA Red 
Laminin 111 Anti-Laminin 
ab11575 
1:100µL in 
BSA 
Goat-Anti Rabbit 
488 
1:500µL in BSA Green 
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Appendix D: Suture Production 
Materials: 
 ECM-fibrin microthreads of all concentrations 
 DI H2O 
 Laboratory Tape 
 Ruler 
 Iris scissors  
 Fine toothed forceps 
 Havel’s regular eye suture needles 
 27 gauge hypodermic needles  
 Blue slide clamps 
 Silastic Silicone tubing (ID: 1.98 mm, OD: 3.18 mm) 
 DPBS 
 SIMCO Air blower (optional) 
 Chex-All sterilization pouches 
Procedure: 
1. On a clean dark surface, gather 12 microthread of the same type together. Align the ends of the 
microthreads so that they are even. Secure all 12 microthreads together with a piece of 
laboratory tape. 
2. Fold the tape in half and secure the cluster of threads to a lab bench-top stand. 
3. Using a disposable pipet, drop water down the microthreads to hydrate them and form them 
together. 
4. Once fully hydrated, twist the microthreads together by twisting from the bottom of the bundle.  
5. After twisting the microthreads together, secure the end of the bundle to the middle bar on the 
lab benchtop stand.  
6. Allow the bundle to dry. 
7. Once dry, remove the bundle from the stand cur off the two ends (the tape and the opposite 
end of the bundle where it was clamped to the stand). 
8. Cut a 5cm section of bundle and thread the section through the eye of a suture needle.  
9. Hydrate the bundle in DPBS for 10 minutes.  
10. Remove the bundle and needle from DPBS.  
11. Fold the bundle in half over the needle and align the two ends. 
12. Using a surgical clamp, secure the two ends of the suture together. 
13. Twist the needle about 4 times to bundle the two sides of the suture together. 
14. Secure the needle with a second surgical clamp. Pull the clamps so that they are at least 2cm 
apart. 
15. Allow the suture to dry. Use the SIMCO Air blower if the sutures are taking a long time to air dry. 
16. Once dry, remove the suture from the clamps and small bit of suture that was clamped off. 
17. Place the suture inside a 4cm section of silicone tubing so that the whole suture is within the 
tubing and the curved portion of the needle is not.  
18. Slide a blue slide clamp over portion of the needle that is within the tubing to secure the tubing 
and suture together. 
19. Insert a 27G hypodermic needle next to the suture in the tubing. 
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20. Place the whole bioreactor inside a Chex-All sterilization pouch along with an extra blue slide 
clamp. 
21. Sterilize the sutures using ethylene oxide gas sterilization. 
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Appendix E: hMSC Seeding Protocol 
Materials: 
 Sterile sutures in seeding bioreactor 
 Sterile DPBS 
 Sterile 20-Gauge hypodermic needles (25X) 
 Sterile 1 mL syringes (approximately 30) 
 Sterile 3 mL syringe 
 hMSCs in culture (passages 5-7) 
 Vented 50 mL conical tube 
 Scilogex Rotator 
Procedure: 
1. Use a sterile 3 mL syringe attached to a sterile 20G needle, draw up approximately 3 mL of 
sterile DPBS 
2. Remove the needle from the syringe and inject approximately 100 uL of sterile PBS into each 
bioreactor by attaching the syringe to the already inserted 27G needle 
3. Ensure all bubbles are eliminated from the bioreactor. 
4. Remove the syringe from the needle. Keep 27G needle in the bioreactor. 
5. Allow 20 min for suture hydration. 
6. While bundle hydrates prepare cell suspension according to cell passaging protocol 
a. Trypsinize cells and perform a cell count 
b. Create a cell suspension of 100,000 cells/100 uL 
c. Alliquot 100 uL of the cell suspension into 0.65 mL microcentrifuge tubes. The number 
of tubes with the cell suspension should be the number of samples that are being 
seeded with cells.  
d. Add 100 uL of fresh media into 0.65 mL microcentrifuge tubes. The number of tubes 
with media only should be the number of control sutures being used. 
7. Use new syringe to remove all sterile PBS from the bioreactor before seeding by drawing the 
DPBS back into the syringe.  
8. Use a sterile 1 mL syringe attached to a sterile 20G needle, draw up the cell suspension or the 
media into the syringe. First pull the syringe plunger back about 0.1 mL to place some air into 
the syringe. Next slowly draw up the cell suspension into the syringe. If the cell suspension has 
been sitting long, tritrate the solution to mix the cells back into suspension. Then slowly inject 
cell suspension (100,000 cells / 100 µL) into the bioreactor. For this, hold the bioreactor leveled 
horizontally. Slowly push the plunger to introduce the cell suspension into the bioreactor. Watch 
the needle in order to know when to stop the plunger. If the air in the syringe is pushed into the 
bioreactor, the cell suspension will exit the tubing of the bioreactor through the open end.  
9. Place the extra slide clamp on the open end of the bioreactor. Situate it so that there is no air 
left after the cell suspension. 
10. After injecting the cell suspension and adding the slide clamp, remove the 27G needle from the 
bioreactor. 
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11. Place the bioreactor into a vented 50 mL conical tube. About 4 sutures can fit in 1 50 mL tube. 
12. Place the bioreactor into the 3D printed conical tube holder. 
13. Place the holder on the Scilogex rotator that is inside the cell incubator. Turn the knob to the 
designated place (this speed equals 4 RPM) and rotate in the incubator for 24 hours. 
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Appendix F: CyQuant Cell Proliferation Assay Protocol 
Materials: 
 Complete MSCGM, Lonza 
 Micropipette 1000µL 
 Micropipette tips for 1000µL micropipette 
 Micropipette 200µL 
 Micropipette tips for 200µL micropipette 
 Drummond® Pipette Aid  
 VWR™ Serological Pipettes 10mL 
 Molecular Probes/Invitrogen #C7026 
 Lysis buffer Invitrogen #C7027 
 Costar® 3599 96 Well Culture Cluster (96 well plate) 
 DPBS (Dulbecco’s Phosphate buffered saline) 
 1.7 mL microcentrifuge tubes 
 Microcentrifuge tube rack 
 Daigger Vortex Genie 2® A. Daigger & Co., INC.  
 VWR Microcentrifuge 
Dilutions: 
1. Using a micropipette, add 1 mL Lysis buffer to 19mL DPBS 
2. Using a micropipette, add 50 µL GR (fluorescent) to 20 mL 1x Lysis buffer   
Procedure:  
Standard Curve Preparation: 
1. Obtain a culture of hMSCs 
2. Aspirate off media, using a Pasteur pipette. 
3. Using a micropipette, add 10 mL of DPBS. 
4. Using a Pasteur pipette, aspirate off DPBS. 
5. Using a micropipette, add 5 mL of trypsin.  
6. Perform a cell count. 
7. Using a micropipette, add as much media as necessary to create a cell suspension of 12,000 
cells/100uL. 
Note: Can change cell concentrations if using/counting larger number of cells. 
8. Add 1000 uL of cell suspension to a 1.7 mL microcentrifuge tube. 
9. Centrifuge cell suspension down at 2,000 rpm for 5 minutes using the microcentrifuge. 
10. Without disrupting the pellet, remove as much media as possible. 
11. Add 1000 µL DPBS. 
12. Centrifuge at 2,000 rpm for 5 min using the centrifuge. 
13. Remove 900 µL.  
14. Freeze at -80°C overnight. 
Note: The sample can be store up to 4 weeks in a -80°C freezer. 
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15. Remove the micrcentrifuge tube from the freezer and allow it to come to room temperature. 
Once thawed place it back in the freezer for at least 1 hour.  
16. In a 96 well plate, place 100 µL of CyQUANT dye/lysis buffer into each well in Columns 1-4, Rows 
B-H.  
17. Add additional 100 µL of CyQUANT buffer to each well of H1-H4.  
18. Remove microcentrifuge tube from freezer. Allow the cell suspension to come to room 
temperature. 
19. Vortex lightly using Vortex Genie 2. 
20. When thawing is complete, add 900 µL of CyQUANT buffer to Standard Curve microcentrifuge 
tube. 
Note: The total volume in the Standard Curve should be 1000 µL. 
21.  Lightly vortex using the Vortex Genie 2®. 
22. Using a micropipette, take up the Standard Curve solution and dispense 200 µL into each of the 
wells A1-A4. 
23. Using a 1000 µL micropipette, take up 100 µL of CyQUANT buffer from the topmost well in a 
Column and dispense it into the well directly beneath it. Mix the solution in each well 6 times. 
Repeat this step through Row G.  
Note: Row H wells have NO standard curve (this is blank).  
24. Using a micropipette, add 100 µL of CyQUANT buffer to each well from A1 to G4.    
Note: This will return the full amount to 200 µL. 
 Preparation of Samples: 
1. After seeding cells on microthreads and incubating, remove materials from bioreactor and place 
each sample into a 1.7 mL microcentrifuge tube. 
Note: At this point, the cells on the microthreads should be ready to be counted.   
Note: Make sure you have seeded a control thread with just media – this will give you a 
baseline fluorescent reading that your calculations depend on. 
2. Using a micropipette, add 500 µL of DPBS. 
3. Centrifuge microcentrifuge tube at 2,000 rpm for 5 minutes. 
4. Using a micropipette, remove 400 µL of DPBS. 
5. Place microcentrifuge tube in microcentrifuge tube rack. 
6. Place rack in -80°C freezer overnight. 
Note: The sample can be store up to 4 weeks in a -80°C freezer. The sample will include 
the thread. Once in freezer, the de-ionized water will lyse the cell membrane leaving the 
DNA behind.  This means no trypsinization is required to remove cells from thread.  
7. Remove rack from freezer. 
Note: Allow microcentrifuge tube and contents to reach room temperature. Do NOT place 
in water bath. Once thawed, place the samples back in the freezer for at least 1 hour. 
8. Remove rack from freezer following re-freeze and allow samples to come to room temperature. 
9. Using a micropipette, add 400 µL of CyQUANT lysis buffer. 
10. Vortex lightly using the Vortex Genie 2®. 
11. Using a micropipette, remove material from sample. 
12. Place materials on a slide for staining. 
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Note: This will confirm cell removal. 
13. Using a pipette, take up of solution with cells and dispense 100 µL solutions into each of 4 wells. 
Start at the wells directly adjacent to the standard curve.  
14. Once all intended wells are complete,  
15. For de-gassing, place in vacuum. This will remove bubbles.  
16. Place 96 well plate on plate reader. 
17. Run plate reader. (480nm excitation, 520nm absorption) 
Note: Samples will saturate after 5 minutes of light exposure; work fast.  
Should be 200 µL in all wells of standard curve, if not add CyQUANT buffer until 200 µL is 
reached.  
18. Dispose of waste properly.  
Calculations: 
1. Copy obtained data into an empty Excel document. Calculate average, correlation coefficient, 
slope, and x-intercept of standard curve. 
Note: To calculate the correlation coefficient type in desired cell (the cell locations 
should correspond to cells for calculation) 
 Ex: =CORREL(A3:A10,F3:F10) 
To calculate the average type in desired cell (the cell locations should correspond to cells for 
calculation)  
Ex: =AVERAGE(B3:BE3) 
To calculate the intercept type in the desired cell (the cell locations should correspond to 
cells for calculation) 
Ex: =INETERCEPT(F3:F10,A3,A10) 
To calculate the slope type in the desired cell (the cell locations should correspond to cells 
for calculation) 
Ex: =SLOPE(F3:F10,A3,A10) 
2. Using average, multiple the average by 5 for 500µL. 
3. Cell value for sample = (Average – y-intercept)/slope. 
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Appendix G: Hoescht and Phalloidin Staining Protocol 
Materials: 
 Phosphate Buffered Saline 
 4% Paraformaldehyde (Only needed for tissues/cells that have not been fixed); 
 0.25% Triton-X 
o 0.25% V/V  Triton-X in PBS 
o 10 μL Triton-X in 3990 μL PBS 
 1% BSA 
o 1% V (W)/V BSA in PBS 
o 40 μL in 3960 μL PBS 
 Phalloidin (AF 488 Phalloidin A12379, Invitrogen) 
o 2.5% V/V Phalloidin in PBS 
o 50 μL in 1950 μL 
 Hoechst 
o 0.0167% Hoechst dye in PBS 
o 0.5 μL in 3000 μL PBS 
Procedure: 
For unfixed sections/cells: 
1. Rinse in PBS x2 
2. Fix in 4% Paraformaldehyde for 10 minutes 
3. Follow directions for fixed sections 
 
For fixed sections/cells: 
1. Rinse with PBS x2 
2. Triton-X solution for 10 minutes 
3. Rinse with PBS x2 
4. Block with BSA solution for 30 minutes 
5. Phalloidin solution for 30 minutes 
6. Rinse with PBS x2 
7. Hoechst solution for 3-5 minutes (typically 3) 
8. Rinse with PBS x2 
9. Cytoseal and coverslip 
10. Store frozen at -20 degrees C. 
Results: 
 F-actin is stained green 
 Nucleus is stained Blue 
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Appendix H: EPOC Outgrowth Assay Protocol 
H.1. Microthread Construct Preparation 
Materials: 
 50 mL conical tubes 
 Scalple handle and blade 
 Bunsen burner (and lighter) 
 Stainless steel washers 
 Medical grade silicone adhesive 
 15% ECM-fibrin microthreads 
 Fibrin microthreads 
 6-well plate 
Procedure: 
1. Obtain 50 mL conical tubes 
2. Using an ignited Bunsen burner, heat the edge of a scalpel blade in the flame. 
3. “cut” the 50 mL conical tube into 1.5 cm sections using the heated blade. 
a. The tube will melt from the heated blade. 
4. Once the sections are cut, place them in a 6-well plate to ensure that they are the proper height. 
The conical tube should NOT touch the surface of the 6-well plate cover. If it is too tall, use the 
scalpel blade to melt down the section or use course sand paper to shorten it. 
5. For one type of microthread, cut 6 3cm sections of the microthread. Glue each section of 
microthread to an individual stainless steel washer using the silicone adhesive. Ensure to use a 
minimal amount of adhesive.  
6. Once dry, glue the microthread-washer combo to one end of the conical tube section using the 
silicone adhesive. Glue the tube so that it is on the same side of the microthread on the washer. 
7. Allow the glue to dry overnight. Place the constructs inside 6-well plates to keep them secure 
and sterilize them using ethylene oxide gas sterilization. 
8. Control constructs should contain a stainless steel washer with a conical tube section and no 
microthread. 
H.2. Plate Preparation and Cell Culture 
Materials: 
 6-well tissue culture plate 
 Complete EPOC media (Biochain) 
 1 vial Endothelial Progenitor Outgrowth Cells (Biochain) 
 sterile ruler 
 sterile laboratory marker 
 1000 uL micropipette 
 1000 uL micropipette tips 
Procedure: 
1. Prior to any cell culture, the 6-well culture plates must be prepared for the outgrowth. 
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2. In order to assess the outgrowth properly, parallel dotted lines must be drawn for imaging. 
3. Obtain a sterile 6-well plate. 
4. Place the plate upside-down, keep the cover on the plate to maintain sterility. 
5. Using the ruler, locate the middle of the well and draw one vertical dotted line down the well 
approximately 1 mm to the left of the middle.  
6. Move the ruler approximately 2 mm to the right and draw another dotted line. Make sure that 
the second line of dots are parallel to the dots in the left side line. These two lines create an 
approximate 2mm channel down the middle of the well. 
7. Repeat for all wells. 
8. Once the lines are drawn, thaw the EPOC vial from the manufacturer. 
9. Perform a cell count and plate between 10,000 and 12,500 cells per cm^2 or approximately 
95,000 to 118,750 cells per well.  
10. Allow the cells to reach full confluency before continuing with outgrwoth experiment. 
H.3. EPOC Outgrowth Assay 
Materials: 
 Complete EPOC Media (BioChain) 
 Endothelial Progenitor Outgrowth Cells (Biochain) 
 Sterile DPBS 
 6-well plate 
 1000 uL micropipette 
 1000 uL micropipette tips 
 200 uL micropipette tips 
 Sterile microthread constructs. 
Procedure: 
1. Obtain a 6-well plate with confluent EPOCs. 
2. Aspirate the media from each well. 
3. Using a 200 uL micropipette tip, scratch the surface of each well in between the two dotted 
lines. Use a new micropipette tip for each well. 
4. Rinse each well with 2000uL of DPBS twice. Swirl the plate in between washes. 
5. Place a sterile microthread construct within the well so that the microthread lies within the 
scratch.  
6. Add 2000uL of complete EPOC media to each well. Add the media to the edge of the well and 
not the middle as to not disturb any cells that lie within the construct. 
7. Confirm that each microthread is within their designated scratch.  
8. For each 6-well plate, there should be 2 fibrin microthread constructs, 2 15% ECM constructs, 
and 2 control constructs. 
9. Evaluate the outgrowth by imaging each well at the individual pairs of dots that lie within the 
construct. Image each well at 0 Hours, 6 Hours, 12 Hours, 18 Hours and 24 Hours. 
10. Following outgrowth, perform a DAPI stain on the microthreads as well as each well.  
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Appendix I: DAPI Staining Protocol 
Materials: 
 DPBS 
 4% Paraformaldehyde 
 0.25% Triton-X 
o 0.25% V/V  Triton-X in PBS 
o 10 μL Triton-X in 3990 μL PBS 
 DAPI 
o STOCK SOLUTION: 10 mg in 2 mL of DiH2O, or 5000 ug/mL 
o Dilute to: 1ug/mL 
 6-well plate from outgrowth assay 
 microthread constructs 
Procedure: 
1. Remove each microthread construct from their respective wells. 
2. Cut the microthread from the construct and place it on a glass slide.  
3. Fix the microthreads and each well in the 6-well plate with 4% paraformaldehyde for 10 
minutes. 
4. Wash the microthreads and wells in DPBS 3 times for 5 minutes each. 
5. Permeabilize with 0.25% Triton-X 100. 
6. Wash in DPBS 3 times for 5 minutes each. 
7. Stain with DAPI for 5 minutes. 
8. Wash in DPBS.  
9. View and analyze under a fluorescent microscope. 
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Appendix J: EPOC Outgrowth Calculations 
The table below shows representative calculations for one well of the EPOC outgrowth assay. These 
calculations were performed for each well in each 6-well plate.  
Well 2_ 15% ECM 2 12.12.16     
Top 0 Hours 6 Hours 12 Hours 18 Hours 24 Hours 
 1144.086 1062.366 911.828 322.581 0 
Scratch mostly complete 1101.075 1152.688 903.226 296.774 0 
At 18 hours. Top and 1174.194 963.441 369.892 0 0 
Bottom still slightly open 1354.839 950.538 529.032 0 0 
 1182.796 881.72 387.097 0 0 
Scratch Complete at 24  1208.602 791.398 417.204 0 0 
hours 1122.581 1148.387 559.14 0 0 
 1148.387 924.731 318.28 0 0 
 1169.892 1092.473 606.452 421.505 0 
 1126.882 1040.86 421.505 486.022 0 
AVERAGE DISTANCE 1173.3334 1000.8602 542.3656 152.6882 0 
  0--6 Hours 6--12 hours 12--18 hours 18--24 hours 0--24 Hours 
Distance Change 172.4732 458.4946 389.6774 152.6882 1173.3334 
Percent Change  15% 39% 33% 13% 100% 
Mid 1      
 1243.011 959.14 623.656 455.914 0 
Scratch mostly complete  1083.871 903.226 606.452 593.548 0 
at 18 hours 1427.957 1156.989 769.892 576.344 0 
 1212.903 1092.473 636.559 541.935 0 
Scratch Complete at 24 1406.452 954.839 262.366 554.839 0 
hours 1062.366 817.204 619.355 382.796 0 
 1144.086 1109.677 941.935 0 0 
 1182.796 1079.57 795.699 0 0 
 1208.602 941.935 959.14 0 0 
 1135.484 959.14 761.29 0 0 
AVERAGE DISTANCE 1210.7528 997.4193 697.6344 310.5376 0 
  0--6 Hours 6--12 hours 12--18 hours 18--24 hours 0--24 Hours 
Distance Change 213.3335 299.7849 387.0968 310.5376 1210.7528 
Percent Change  18% 25% 32% 26% 100% 
Mid 2      
 1195.699 929.032 800 541.935 503.226 
Scratch partially  1182.796 903.226 645.161 455.914 400 
Complete at 24 hours 1333.333 984.946 847.312 404.301 481.72 
 1290.323 1079.57 490.323 391.398 391.398 
 1320.43 980.645 713.978 335.484 430.108 
 1277.419 950.538 1002.151 752.688 387.097 
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 1281.72 1092.473 877.419 838.71 0 
 1088.172 1208.602 920.43 701.075 0 
 1148.387 1015.054 821.505 593.548 0 
AVERAGE DISTANCE 1235.6989 1023.2258 804.7311 572.0429 259.3549 
  0--6 Hours 6--12 hours 12--18 hours 18--24 hours 0--24 Hours 
Distance Change 212.4731 218.4947 232.6882 312.688 976.344 
Percent Change  17% 18% 19% 25% 79% 
Bottom      
 1458.065 1113.978 739.785 838.71 533.333 
Scratch partially closed 1359.14 1040.86 967.742 718.28 589.247 
At 24 hours 1221.505 1238.71 1092.473 774.194 0 
 1273.118 1092.473 1040.86 447.312 0 
 1470.968 1212.903 937.634 412.903 0 
 1307.527 1040.86 984.946 692.473 0 
 1522.581 1191.398 890.323 726.882 0 
 1518.28 1294.624 1002.151 860.215 0 
 1470.968 1247.312 1148.387 632.258 0 
 1436.559 1243.011 972.043 434.409 0 
AVERAGE DISTANCE 1403.8711 1171.6129 977.6344 653.7636 112.258 
  0--6 Hours 6--12 hours 12--18 hours 18--24 hours 0--24 Hours 
Distance Change 232.2582 193.9785 323.8708 541.5056 1291.6131 
Percent Change  17% 14% 23% 39% 92% 
TOTAL AVERAGE 1255.91405 898.152717 755.591375 444.675709 92.903225 
STD DEVIATION 129.300400 347.278449 231.594123 291.198337 190.796957 
      
TOTAL CHANGE AVG 207.6345 292.688175 333.3333 329.35485 1163.01082 
STD DEVIATION 25.1564058 119.4297642 73.6752934 160.053031 133.876685 
 Total % Change at 24hrs         93% 
 
